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Abstract 
Central chondroid bone tumours are one of the most common primary bone 
tumours. Benign central chondroid tumours are termed enchondromas and its 
malignant counterpart are called chondrosarcomas. Enchondromas are frequently 
observed on routine imaging.  Similarly, chondrosarcomas are the second most 
common primary bone tumour after osteosarcoma. Imaging is crucial in the diagnosis 
of central chondroid tumours and in the differentiation of enchondromas from 
chondrosarcomas. Furthermore, imaging plays a vital role in the staging of 
chondrosarcomas. In this thesis, the published scientific literature on the role of 
imaging in the diagnosis of benign chondroid tumours and chondrosarcomas and the 
role of imaging in the staging of chondrosarcomas is reviewed and summarised. 
Furthermore, the contribution of the authors’ published work is highlighted in the 
thesis. 
The first two articles are review articles which discuss the clinical and imaging 
features of benign and malignant chondrogenic tumours and the significance of 
imaging in the diagnosis of these tumours.  
The third article is an original article which investigates the theory of the 
pathogenesis of enchondromas. It is widely believed that enchondromas arise from 
cartilage islands which are displaced from the growth plate during the process of 
skeletal maturation.  However, this theory is unproven, and the origin of this theory 
was forgotten prior to the authors’ study. Based on the incidental prevalence of 
enchondromas of the knee in the adult population of 2.9%, the study assesses the 
prevalence of cartilage islands/enchondromas in skeletally immature patients. In this 
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study, no cartilage islands/enchondromas in skeletally immature patients were 
identified. The study therefore shows the rarity of enchondromas in skeletally 
immature individuals which is in contrast to the adult population. Furthermore, in 
view of the absence of cartilage islands in this study, the study raises doubts about 
the validity of the unproven theory. Lastly, the very origin of this theory is 
rediscovered in this thesis which has been forgotten in modern medicine.  
The fourth article is an original article which evaluates the role of diffusion-weighted 
MRI (DWI) in the diagnosis of central cartilage tumours. Prior to the authors’ study 
the role of DWI in the diagnosis of central cartilage tumours was uncertain. The 
authors’ study demonstrates that DWI cannot be used to differentiate between 
enchondromas and chondrosarcomas and that DWI does not aid in the distinction of 
low-grade chondroid tumours from high-grade chondrosarcomas. This is a finding 
which was not known prior to the study. 
The fifth article is an original article which assesses the utility of conventional MRI in 
the differentiation of low-grade from high-grade chondrosarcomas of long bone. 
Prior to the authors’ study the role of conventional MRI in the differentiation of low-
grade from high-grade chondrosarcomas of long bone was unknown. The authors’ 
study shows that bone expansion, active periostitis, soft tissue mass and tumour 
length can be used to differentiate high-grade from low-grade chondral lesions of 
long bone on conventional MRI. Furthermore, the presence of these four MRI 
features shows a diagnostic accuracy of 95.6%.  These findings were not known prior 
to the study and have significantly furthered the knowledge about the role of 
conventional MRI in the grading of chondrosarcoma of long bone.  
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The sixth article is an original article which evaluates the role of bone scintigraphy 
and Computed Tomography of the chest in the staging of chondrosarcoma of bone. 
Whilst guidelines regarding the staging of bone sarcomas state that bone 
scintigraphy should be performed to assess for the presence of skeletal metastases 
and that Computed Tomography (CT) of the chest should be performed to evaluate 
for possible pulmonary metastases, there has been no research on the utility of bone 
scintigraphy in chondrosarcoma of bone and on the role of CT-chest in the staging of 
chondrosarcomas.  Furthermore, the prevalence of skeletal and pulmonary 
metastases of chondrosarcoma at presentation was unknown prior to this study. The 
authors’ study demonstrated no skeletal metastases on bone scintigraphy in 
chondrosarcoma of bone at presentation. In contrast, pulmonary metastases were 
observed in approximately 5% of all patients with chondrosarcoma at presentation 
on CT-chest. The finding therefore demonstrates the rarity of skeletal metastases in 
chondrosarcoma of bone at presentation which is in contrast to osteosarcoma and 
Ewing sarcoma. The study therefore concludes that there is little role for skeletal 
scintigraphy in the surgical staging of chondrosarcoma. In contrast, the study shows 
that there is a role for CT-chest in the staging of chondrosarcoma. These above 
described findings are important new findings and represent a significant 
contribution to the knowledge base regarding metastatic behaviour of 
chondrosarcomas at presentation and regarding the staging of chondrosarcoma of 
bone.  
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In summary, the authors’ publications have significantly enhanced and furthered the 
understanding of the pathogenesis of enchondromas, the role of functional MRI in 
the differentiation of enchondromas from chondrosarcomas, the utility of MRI in the 
grading of chondrosarcomas and the role of skeletal scintigraphy in the staging of 
chondrosarcomas.  
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Foreword 
Primary bone tumours are a heterogeneous group of tumours, which originate in 
bone or from bone-derived cells. Whilst benign primary bone tumours are relatively 
common, malignant primary bone tumours (bone sarcomas) represent a rare disease 
entity. Primary bone tumours are classified according to the World Health 
Organization Classification of Tumours dependent on their histological composition. 
Chondrogenic tumours represent a subgroup of bone tumours, which demonstrate 
cartilaginous differentiation and are amongst the most common primary bone 
tumours.  Enchondroma is a benign bone tumour of hyaline cartilage which 
represents the second most common benign bone tumour after osteochondroma 
whilst its malignant counterpart, the chondrosarcoma is a malignant cartilaginous 
matrix-producing neoplasm which represents the second most common sarcoma of 
bone after osteosarcoma. Imaging plays a pivotal role in the detection, diagnosis and 
staging of bone tumours in general and in chondrogenic bone tumours in particular. 
This is highlighted by the fact that unlike in carcinomas where histopathological 
evaluation is the gold standard in the diagnosis of tumours, the diagnosis of bone 
tumours is reliant on a consensus between histopathology and imaging. This is of 
particular importance in chondrogenic tumours where the differentiation of benign 
chondrogenic tumours (enchondromas) from malignant chondrogenic tumours 
(chondrosarcomas) is one of the most challenging diagnoses in orthopaedic oncology 
and is based on a consensus between clinical findings, imaging and histopathology.   
Imaging, may it be Radiography, Computed Tomography, Magnetic Resonance 
Imaging, Skeletal Scintigraphy and more recently Positron Emission Tomography has 
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revolutionized oncology including the care of patients with sarcoma as it facilitates 
early detection, diagnosis and staging of cancers thereby significantly contributing to 
the marked improvement in survival of oncology patients which has been observed 
over the last 40 years.   
Although there is a plethora of evidence supporting the role of imaging in the 
diagnosis, grading and staging in a wide variety of cancers, the evidence in 
chondrosarcomas has been very limited. In particular, there has been a paucity of 
evidence to support the use of functional imaging techniques in the diagnosis of 
chondrosarcomas. 
This thesis discusses four original studies and two review articles published by the 
author of this thesis which evaluate; 
1) the significance of imaging in benign and malignant chondrogenic tumours in 
general 
2) the contribution of MR Imaging in understanding the pathogenesis of 
enchondromas  
3) the role of functional MRI in the diagnosis of chondrosarcomas 
4) the significance of conventional MRI in the grading of chondrosarcomas 
5) the utility of skeletal scintigraphy in the staging of chondrosarcomas in 
particular 
All original articles and review articles have been published in peer-reviewed journals 
and all original articles represent significant contributions to the knowledge 
regarding the pathogenesis of enchondromas, the diagnosis, grading and staging of 
chondrosarcomas. Furthermore, the hereby presented original articles about the role 
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of imaging in the diagnosis, grading and staging of chondrosarcomas have resulted in 
significant changes in patient management. Lastly, the authors’ work, which is being 
presented for this thesis, has been quoted in multiple national and international 
conferences and has been cited in multiple peer-reviewed publications and books.   
The publications form part of the research portfolio of the applicant and are closely 
related in that they are all imaging research studies on primary chondrogenic bone 
tumours. The introduction aims to provide both an overview of the topic and a 
summary of the publications presented describing the role of imaging in the 
diagnosis, grading and staging of chondrogenic bone tumours prior to the authors’ 
published work. Furthermore, the limitations of imaging in the diagnosis and in the 
work-up of patients with chondrogenic tumours are being discussed.  
Subsequently, the presented work of the author demonstrates the significance and 
contribution of the authors’ published work in understanding the pathogenesis of 
enchondromas, the role of imaging in the diagnosis, grading and staging of 
chondrosarcomas.  In the conclusion, the author discusses the potential future role 
of other advanced imaging techniques in the diagnosis of enchondromas and 
chondrosarcomas and in the potential role of treatment response in 
chondrosarcomas. 
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Chapter 1: Introduction
1.1. Primary bone tumours
Primary bone tumours are divided into benign primary bone tumours, intermediate 
and malignant primary bone tumours. Whilst benign primary bone tumours are 
relatively common, intermediate and malignant primary bone tumours are rare 
disease entities. The true incidence of benign primary bone tumours is unknown 
because many benign bone neoplasms are clinically indolent and are frequently only 
depicted as incidental findings on imaging performed for unrelated causes. In 
contrast, primary malignant bone neoplasms (sarcomas) are rare and account for 
approximately 0.2% of all neoplasms with an annual incidence of approximately 0.8 
per 100000 population.1-3
According to the World Health Organization, primary bone tumours are classified 
dependent on histopathology. Hence, we differentiate chondrogenic, osteogenic, 
fibrogenic, fibrohistiocytic, haematopoietic, osteoclastic giant cell rich, notochordal, 
vascular, myogenic, lipogenic tumours, tumours of undefined neoplastic nature and 
miscellaneous tumours. The various histological subtypes of primary bone tumours 
are then further classified dependent on their biological behaviour as benign, 
intermediate and malignant (Table 1).4
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Table 1: WHO classification of bone tumours (adapted from World Health Organization Classification 
of Tumours of Soft Tissue and Bone, 2013) 
CHONDROGENIC TUMOURS FIBROGENIC TUMOURS 
Benign Intermediate (locally aggressive) 
Osteochondroma Desmoplastic fibroma of bone 
Chondroma Malignant 
     Enchondroma Fibrosarcoma of bone 
     Periosteal chondroma FIBROHISTIOCYTIC TUMOURS 
Osteochondromyxoma Benign fibrous histiocytoma/Non-ossifying fibroma 
Subungeal exostosis HAEMATOPOIETIC NEOPLASMS 
Bizarre parosteal osteochondromatous proliferation Malignant 
Synovial chondromatosis Plasma cell myeloma 
Intermediate (locally aggressive) Solitary plasmacytoma of bone 
Chondromyxoid fibroma Primary non-Hodgkin lymphoma of bone 
Atypical cartilaginous tumour/Chondrosarcoma 
grade 1 
GIANT CELL RICH TUMOURS 
Intermediate (rarely metastasizing) Benign 
Chondroblastoma Giant cell lesion of small bones 
Malignant Intermediate (locally aggressive, rarely metastasizing) 
Chondrosarcoma grade 2 and 3 Giant cell tumour of bone 
Dedifferentiated chondrosarcoma Malignant 
Mesenchymal chondrosarcoma Malignancy in giant cell tumours of bone 
Clear cell chondrosarcoma NOTOCHORDAL TUMOURS 
OSTEOGENIC TUMOURS Benign  
Benign Benign notochordal tumour 
Osteoma Malignant 
Osteoid osteoma Chordoma 
Intermediate (locally aggressive) VASCULAR TUMOURS 
Osteoblastoma Benign 
Malignant Haemangioma 
Low-grade central osteosarcoma Intermediate (locally aggressive, rarely metastasizing)
Conventional osteosarcoma Epithelioid haemangioma 
     Chondroblastic osteosarcoma Malignant 
     Fibroblastic osteosarcoma Epithelioid haemangioendothelioma 
     Osteoblastic osteosarcoma Angiosarcoma 
Telangiectatic osteosarcoma TUMOURS OF UNDEFINED NEOPLASTIC NATURE 
Small cell osteosarcoma Benign 
Secondary osteosarcoma Simple bone cyst 
Parosteal osteosarcoma Fibrous dysplasia 
Periosteal osteosarcoma Osteofibrous dysplasia 
High-grade surface osteosarcoma Chondromesenchymal hamartoma 
MYOGENIC Rosai-Dorfman disease 
Benign Intermediate (locally aggressive) 
Leiomyoma of bone Aneurysmal bone cyst 
Malignant Langerhans cell histicytosis 
Leiomyosarcoma of bone      Monostotic 
LIPOGENIC      Polyostotic 
Benign Erdheim-Chester disease 
Lipoma of bone MISCELLANEOUS TUMOURS 
Malignant Ewing sarcoma 
Liposarcoma of bone Adamantinoma 
Undifferentiated high-grade pleomorphic sarcoma 
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Benign bone tumours are characterized by a limited capacity of local recurrence 
whilst intermediate tumours often recur and are associated with an infiltrative and 
locally destructive growth pattern but do not metastasize or rarely metastasize. In 
contrast, malignant bone tumours (termed bone sarcomas) in addition to 
demonstrating a locally destructive growth and recurrence also have a significant risk 
to metastasize which ranges from approximately 20% to 100%.1,4 Chondrosarcomas, 
osteosarcomas, leiomyosarcomas and fibrosarcomas of bone are further graded 
based on their histopathological features such as relative proportion of cells to 
matrix, nuclear atypia of tumour cells, irregularity of nuclear contour, enlargement 
and hyperchromasia of nuclei, mitotic figures and necrosis. The two histopathological 
grading systems which are most widely adopted are the two-tier system which 
divides malignant tumours as low-grade and high-grade and the three-tier system 
which divides malignant bone tumours into grade 1, grade 2 and grade 3 malignant 
bone tumours.1
1.2 Chondrogenic tumours 
Chondrogenic bone tumours are tumours which consist of cartilage and they 
represent the second largest group of bone tumours after osteogenic bone tumours. 
Benign chondrogenic bone tumours include osteochondroma, enchondroma, 
periosteal chondroma, chondromyxoid fibroma, osteochondromyxoma, bizarre 
parosteal osteochondromatous proliferation, synovial chondromatosis and the 
chondroblastoma. In contrast, malignant chondrogenic tumours include 
chondrosarcomas (grade 1-3), periosteal chondrosarcoma, dedifferentiated 
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chondrosarcoma, mesenchymal chondrosarcoma and clear cell chondrosarcoma 
(see Table 1). In the following sections, I will focus on one of the most common 
benign cartilage tumours, the enchondroma and its malignant counterpart, the 
central chondrosarcoma.  
1.2.1 Enchondroma 
Enchondroma is a benign hyaline cartilage neoplasm which arises in the medullary 
cavity.  
1.2.1.1 Epidemiology of enchondromas 
Enchondromas are relatively common and account for approximately 10-25% of all 
surgically removed benign bone tumours.5 The true incidence is significantly higher 
because many enchondromas are asymptomatic and are frequently only discovered 
incidentally. This has been highlighted in two previous MRI-studies which discovered 
that the incidental prevalence of enchondromas on routine MRI-examinations of the 
knee is 2.9%6 and the incidental prevalence of enchondromas on routine MRI-
examinations of the shoulder is 2.1%7. In contrast, enchondromatosis, which is a 
group of skeletal dysplasias characterized by multiple enchondromas and which 
includes Ollier’s disease and Maffucci syndrome are rare disease entities.8 An in-
depth discussion of enchondromatosis is beyond the remit of this thesis. I will 
therefore focus on solitary enchondromas in this thesis unless particularly stated.  
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Enchondromas demonstrate a wide age distribution which ranges from 5 years to 80 
years although the average age at time of diagnosis is 40 years.9,10
1.2.1.2 Location and clinical presentation of enchondromas  
The most common location of  enchondromas are the long tubular bones of the hand 
(40-65% of all enchondromas) followed by the major long bones (approximately 25% 
of all enchondromas) with the femur being the most common location within the 
long bones followed by the humerus and tibia.  Furthermore, 7% of all enchondromas 
are located within the feet. In contrast, enchondromas are rare in the flat bones such 
as the pelvis, spine, ribs, scapula and sternum. 9 Whilst enchondromas in the hands 
and feet may present clinically with palpable swelling or a pathological fracture, 
enchondromas of the long tubular bones are often asymptomatic and are therefore 
frequently detected incidentally. 6,7,9,10
1.2.1.3 Histology of enchondromas 
On histopathology, enchondromas are hypocellular, avascular hyaline tumours, 
which demonstrate abundant hyaline cartilage without cellular atypia (Figure 1). 
Endosteal erosion may be present in some cases however an important 
differentiating feature from chondrosarcomas is the lack of entrapment of the host 
bone by tumour cells. In contrast to enchondromas of long bone, enchondromas of 
the hands and feet can be more cellular and may demonstrate cellular atypia.11
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Figure 1: 
Figure 1: Histopathology of enchondroma: Histology shows well-differentiated, hypocellular, 
avascular hyaline cartilage without cellular atypia and no host bone entrapment. (Image 
courtesy of Dr F. Puls, Department of Pathology, Royal Orthopaedic Hospital, Birmingham, 
UK). 
1.2.1.4 Pathogenesis of enchondromas  
The pathogenesis of enchondromas is poorly understood. Although it is widely 
believed that enchondromas arise from cartilage remnants, which have been 
displaced from the growth plate during the process of skeletal maturation, this 
widely held belief is unproven and the origin of this theory is unknown in modern 
medicine.12 In chapter 4 of this thesis, I investigate the origin of this theory 
unravelling unexpected and surprising findings into the very origin of this theory and 
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critically appraise the origin of this theory. Furthermore, we investigate the theory 
using MRI.  
1.2.1.5 Imaging of enchondromas  
Imaging is crucial in the identification and diagnosis of enchondromas. 
Enchondromas of long bones are usually located centrally or eccentrically in a 
metadiaphyseal location whilst epiphyseal involvement is only observed in 2-5% of 
all enchondromas of long bones.  On radiography, enchondromas usually appear as 
well-defined lytic lesions within the medullary cavity which demonstrate a 
geographic pattern of bone destruction.9 Approximately 95% of all enchondromas in 
the long bones demonstrate some degree of matrix calcification which is typically 
referred to as ring-and-arc or popcorn calcification.13 Enchondromas are usually less 
than 5cm in maximum length, demonstrate only minimal endosteal scalloping and 
minimal cortical thickening (Figure 2).10 Periosteal reaction, bone expansion and 
cortical destruction are not features of central intramedullary enchondromas of long 
bones and if present are suspicious for the development of a chondrosarcoma13,14.  
In contrast to enchondromas of long bones, enchondromas in the hands and feet 
frequently demonstrate extensive endosteal scalloping, bony expansion and cortical 
thinning (Figure 3). These findings should therefore not be used to raise the suspicion 
for the development of a chondrosarcoma in the hands and feet. Furthermore, it may 
be difficult to demonstrate a calcified matrix in enchondromas of the hand unlike in 
enchondromas of the long bones. In the absence of trauma however, cortical 
disruption and periosteal reaction are unusual in enchondromas of the hands and 
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feet and therefore raise the suspicion of malignant transformation into a 
chondrosarcoma.10,13
Figure 2:  
Figure 2:  Radiograph of enchondroma of the proximal tibia: Anteroposterior 
radiograph of the knee demonstrates a 4.3cm in the maximum cranio-caudal 
dimension measuring enchondroma within the proximal tibia which shows chondroid 
matrix calcification (arrow) but no endosteal scalloping, cortical destruction or 
periosteal reaction. 
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Figure 3: 
Figure 3: Radiograph of enchondroma of the hand: Anteroposterior radiograph of the little 
finger demonstrates an expansile radiolucent lesion of the middle phalanx which shows 
marked endosteal scalloping, cortical thinning and bony expansion with subtle foci of matrix 
calcification within it (arrow). The imaging findings are in keeping with an enchondroma. 
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Computed Tomography is useful in demonstrating radiographically occult matrix 
calcification in enchondromas (Figure 4) and is the imaging modality of choice in the 
assessment of the degree of endosteal scalloping if present.10,13
Figure 4: 
Figure 4: Computed Tomography of enchondroma of the femur. Sagittal CT of an 
enchondroma of the distal femur demonstrates extensive chondroid matrix calcification 
(arrow) but no endosteal scalloping  
29 
On MRI, enchondromas of long bones typically demonstrate a well-defined lobular 
contour, with the lesion appearing as intermediate signal intensity on the T1-
weighted images and of increased signal intensity on the T2-weighted images in 
keeping with hyaline cartilage (Figure 5a,b). Small foci of high signal intensity on the 
T1-weighted images may be observed within the lesion (Figure 5a) and are thought 
to represent engulfed normal yellow marrow.. On MRI, matrix calcification if present 
appears as punctate or curvilinear foci of signal void both on T1-weighted images and 
fluid-sensitive sequences (Figure 6a,b). 10,13 Thin septa which are of low-signal 
intensity on the T2-weighted images, are often seen between lobules of cartilage and 
demonstrate fibrovascular septa which enhance after gadolinium administration 
(Figure 6c).
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Figure 5: 
Figure 5a:                                                                   Figure 5b: 
Figure 5: MRI of enchondroma of the distal femur: Coronal T1W SE MRI (a) and coronal T2W 
FS MRI (b) of an enchondroma of the distal femur shows a well-defined lobulated lesion 
which is of low to intermediate signal intensity on the T1-weighted images (a, small arrow) 
and of increased signal intensity on the T2 fat-suppressed images (b, small arrow). There are 
small foci of high signal intensity on the T1-weighted images, (a, large arrow) which represent 
foci of engulfed normal yellow marrow. 
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Figure 6:  
Figure 6a:              Figure 6b: 
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Figure 6c: 
 Figure 6: MRI of enchondroma of the distal femur. Coronal T1W SE MRI (a) and 
coronal T2W FS MRI (b) of an enchondroma of the distal femur demonstrates a 4.9cm 
chondroid lesion which shows foci of signal void both on the T1-weighted image (a, 
arrow) and on the T2 fat-suppressed images (b, arrow) in keeping with matrix 
calcification. Gadolinium-enhanced fat-suppressed T1-weighted MRI examination of 
the same lesion shows avid peripheral and septal enhancement (c, arrow) as well as 
nodular enhancement. 
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On 99m-Technitium methylene diphosphonate (MDP) bone scintigraphy, 
enchondromas usually demonstrate mild to moderate homogeneous radio-isotope 
uptake which is equal or less than the radio-isotope uptake observed within the 
anterior iliac crest (Figure 7a,b). However approximately 30% of all enchondromas 
demonstrate avid heterogeneous radio-isotope uptake on 99m-Technitium 
methylene diphosphonate (MDP) bone scintigraphy which is greater than the uptake 
observed in the anterior iliac crest (Figure 8).9,10,13,15 Hence, this finding cannot be 
reliably utilized to differentiate enchondromas from low-grade chondrosarcomas.  
34 
Figure 7: 
Figure 7a:                                          Figure 7b: 
Figure 7: MRI and bone scintigraphy of enchondroma of the left distal femur. Coronal T1W 
SE MRI of the left femur (a) demonstrates a 4.5cm in the maximum cranio-caudal dimension 
measuring enchondroma in the distal femur. On 99m-Technitium methylene diphosphonate 
(MDP) bone scintigraphy, the lesion demonstrates only mild homogeneous radio-isotope 
uptake (b, black arrow) which is less than the radio-isotope uptake observed within the 
anterior iliac crest. 
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Figure 8: 
Figure 8: Bone scintigraphy of enchondroma of the left distal femur. 99m-Technitium 
methylene diphosphonate (MDP) bone scintigraphy of the enchondroma of the distal femur 
seen in figure 6 demonstrates avid radio-isotope uptake (black arrow). 
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On fluoro-deoxyglucose-positron emission tomography (FDG-PET), enchondromas 
demonstrate mildly increased mean standardized uptake value. However, there is 
considerable overlap in the SUVmax values between enchondromas and low-grade 
chondrosarcomas resulting in a poor specificity when SUVmax values fall between 2 
and 4.5 which is observed in approximately 46% of all benign and malignant 
chondroid lesions.16,17
1.2.1.6 Management of enchondromas 
Unlike chondrosarcomas which always require surgical intervention unless surgery is 
contraindicated, the management of enchondromas is dependent on patient 
symptoms. Asymptomatic enchondromas do not require treatment. In contrast, 
symptomatic enchondromas can be safely treated with curettage.18
1.2.2 Chondrosarcoma 
1.2.2.1 Epidemiology of chondrosarcomas 
Chondrosarcomas are the second most common malignant primary bone tumour 
after osteosarcoma accounting for approximately 20% of all malignant bone tumours 
and for 3.5% of all biopsied primary bone tumours.14 According to the WHO 
Classification of bone tumours, chondrosarcomas are defined as “a locally aggressive 
or malignant group of cartilaginous matrix-producing neoplasms with diverse 
morphological features and clinical behaviour”.19 Chondrosarcomas are divided into 
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conventional chondrosarcomas, dedifferentiated chondrosarcomas, mesenchymal 
chondrosarcomas and clear cell chondrosarcomas.4 Conventional chondrosarcomas 
are further divided dependent on location and origin into primary central 
chondrosarcomas, secondary central chondrosarcomas, secondary peripheral 
chondrosarcomas and periosteal chondrosarcomas.19 Primary central 
chondrosarcomas are chondrosarcomas, which arise centrally in bone without a 
benign precursor whilst secondary central chondrosarcomas are central 
chondrosarcomas, which arise in a pre-existing enchondroma. In contrast, secondary 
peripheral chondrosarcomas are chondrosarcomas which arise from an 
osteochondroma whilst periosteal chondrosarcomas originate from the periosteum 
and hence occur on the surface of bone.19 Although the above described 
classification reveals a significant variety of chondrosarcomas, primary central 
chondrosarcoma is the most common subtype of chondrosarcoma accounting for 
approximately 85% of all chondrosarcomas. In this thesis, I will therefore focus on 
“primary central chondrosarcoma” and will refer to it as “chondrosarcoma” unless 
otherwise stated.  
1.2.2.2 Location and clinical presentation of chondrosarcomas 
Most patients diagnosed with chondrosarcoma are in their 6th decade of life. 
Although the lesion can arise in any bone which is derived from endosteal 
ossification, the most common sites in the skeleton are the pelvis, followed by the 
proximal femur, proximal humerus, distal femur and ribs.19 In contrast, 
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chondrosarcomas of the hands and feet are rare.20 Similarly, chondrosarcoma in the 
spine and the craniofacial bones are a rare occurrence.21
The most frequent clinical presentations are pain and local swelling which are usually 
present for months prior to diagnosis.15,19 Pathological fracture is observed in 3-17% 
of all chondrosarcomas.14
1.2.2.3 Histology of chondrosarcomas 
On macroscopy, chondrosarcomas have a translucent, lobular blue-gray or white 
surface which corresponds to hyaline cartilage. Yellow-white foci are frequently 
identified within the lesion and represent areas of mineralization. Cortical erosion 
and destruction, bone expansion and an associated soft tissue mass may be seen 
(Figure 9).19
On histology, the tumour is composed of irregularly shaped lobules of hyaline 
cartilage which vary in size and shape.19,22 The chondrocytes demonstrate atypia, 
show enlarged hyperchromatic nuclei and frequently demonstrate myxoid change. 
The presence of host bone entrapment (= permeation of cortical and/or medullary 
bone) is diagnostic of a chondrosarcoma (Figure 10). In cases where permeation is 
not identified but cellular atypia is present, the diagnosis of a low-grade 
chondrosarcoma cannot be reliably made however a low-grade chondrosarcoma 
cannot be excluded. The classification of these low-grade chondroid tumours 
remains controversial. Whilst the latest WHO classification of bone tumours does not 
mention these lesions as a separate disease entity, they invariably are being classified 
in some centres as enchondromas, in others as grade 1 chondrosarcomas despite the 
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lack of a permeative growth pattern whilst other institutions classify them as atypical 
enchondromas, borderline cartilage tumours, grade 0 chondrosarcomas  or as 
cartilaginous tumours of unknown malignant potential (CLUMPs) (Figure 11).19,23-25
The histological criteria for the diagnosis of a chondrosarcoma of the phalanges are 
different and reliant on the presence of cortical destruction, soft tissue extension or 
the presence of mitosis.19,20
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Figure 9: 
Figure 9: Macroscopic pathology of a chondrosarcoma of the humerus. Surgical specimen of 
a coronally sectioned humerus demonstrates lobular white or blue-grey foci of hyaline 
cartilage within the medullary cavity of the humerus (long, white arrow). Yellow-white foci 
(green arrow), which are seen within the lesion represent areas of mineralisation. The lesion 
results in bone expansion, cortical remodelling (curved white arrow) and a soft tissue mass 
(small, thick arrow). (Image courtesy of Dr S. Vaiyapuri, Department of Pathology, Royal 
Orthopaedic Hospital, Birmingham, UK). 
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Figure 10: 
Figure 10: Histopathology of a grade 1 chondrosarcoma: The specimen demonstrates the 
hallmark of a grade 1 chondrosarcoma: the presence of host bone entrapment or 
permeation (black arrows). (Image courtesy of Dr F. Puls, Department of Pathology, Royal 
Orthopaedic Hospital, Birmingham, UK). 
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Figure 11: 
Figure 11: Histopathology of a cartilaginous lesion of unknown malignant potential (CLUMP). 
The chondrocytes demonstrate atypia and myxoid change. There is however no host bone 
entrapment. (Image courtesy of Dr S. Vaiyapuri, Department of Pathology, Royal 
Orthopaedic Hospital, Birmingham, UK). 
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Conventional intramedullary chondrosarcomas are graded on a scale from I to III.  
The grading is based on nuclear size, hyperchromasia, cellularity and mitosis. Grade 
I chondrosarcomas are moderately cellular and contain hyperchromatic nuclei 
(Figure 10). Grade II chondrosarcomas are more cellular demonstrating more nuclear 
atypia, hyperchromasia and nuclear size (Figure 12). Grade III chondrosarcomas show 
increased cellularity, are more pleomorphic, demonstrate increased mitoses and 
show spindle shape at the periphery of the cartilage lobules (Figure 13).19 Grading of 
chondrosarcomas is important because the grade of the lesion correlates with 
prognosis and overall survival.19,26-30 This fact has been highlighted in multiple 
studies, most recently in a large retrospective study which demonstrated that the 10-
year survival of grade I chondrosarcomas was 95%, the 10-year survival for grade 2 
chondrosarcomas was 86% whilst the 10-year survival for grade 3 chondrosarcomas 
was 55%.31
A large study of chondrosarcomas identified that 61% of all chondrosarcomas were 
grade I chondrosarcomas, 36% were grade II chondrosarcomas whilst only 3% were 
grade III chondrosarcomas.32
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Figure 12: 
Figure 12: Histopathology of a grade 2 chondrosarcoma: The chondrocytes demonstrate 
more nuclear atypia and hyperchromasia. (Image courtesy of Dr F. Puls, Department of 
Pathology, Royal Orthopaedic Hospital, Birmingham, UK). 
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Figure 13: 
Figure 13: Histopathology of a grade 3 chondrosarcoma: The tumour cells are more 
pleomorphic and increasingly spindle shaped. (Image courtesy of Dr F. Puls, Department of 
Pathology, Royal Orthopaedic Hospital, Birmingham, UK). 
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1.2.2.4 Pathogenesis of chondrosarcomas 
The pathogenesis of chondrosarcomas remains poorly understood. However, a 
previous study has demonstrated that somatic mutations in isocitrate 
dehydrogenase (IDH) 1 and 2 are frequent events in central chondrosarcomas, 
central and periosteal chondromas occurring in at least 56% of these tumours.  In 
contrast, osteochondromas, peripheral chondrosarcomas and mesenchymal 
tumours other than central chondrosarcomas, central and periosteal chondromas do 
not show this mutation.33 Mutations in IDH 1 and 2 result in production of the 
oncometabolite 2-Hydroxyglutarate (2-HG) which in turn drives tumour progression.  
The exact mechanism by which accumulation of 2-HG may lead to tumourigenesis 
remains uncertain. However, increasing evidence suggests a possible epigenetic 
mechanism. The above described findings therefore suggest a causal role of IDH1 and 
2 mutations in tumourigenesis of central chondrosarcomas.33 In the future, this 
discovery may therefore potentially result in the development of drugs which target 
and effectively treat chondrosarcomas showing IDH 1 and 2 mutations. 
1.2.2.5 Imaging of chondrosarcomas 
Imaging is crucial in the diagnosis of central chondrosarcomas. On radiography, 
chondrosarcomas typically demonstrate as mixed lytic and sclerotic lesions with a 
variable degree of chondroid matrix mineralization which is seen in 60-78% of all 
chondrosarcomas (Figure 14).14,15,19,21
47 
Figure 14: 
Figure 14:  
Radiograph of low-grade chondrosarcoma of distal femur.   Anteroposterior radiograph of 
the distal femur demonstrates a well-demarcated, geographical pattern of bone 
destruction (large arrow) within the distal femur with extensive chondroid matrix 
calcification (small arrow). 
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The amount of calcification is variable, however high-grade chondrosarcomas 
demonstrate less chondroid matrix mineralization than low-grade chondrosarcomas. 
Low-grade chondrosarcomas frequently show a geographical pattern of bone 
destruction (Figure 14) whilst a moth-eaten, permeative pattern of bone destruction 
favours a high-grade chondrosarcoma or a dedifferentiated chondrosarcoma (Figure 
15).10,14.  
Erosion of the cortex is termed “endosteal scalloping”. Endosteal scalloping of more 
than two thirds of the depth of the cortex is a hallmark of chondrosarcoma reflecting 
its increased biological activity (Figure 15). 
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Figure 15: 
Figure 15: Radiograph of a high-grade chondrosarcoma (grade 2 chondrosarcoma) of the 
femur. Lateral radiograph of the femur shows a moth-eaten, permeative pattern of bone 
destruction within the mid-diaphysis with marked endosteal scalloping (large arrow) and 
bone expansion. A relatively small focus of chondroid-matrix calcification (small arrow) is 
observed within the lesion. 
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Continued growth of the lesion may result in cortical remodeling, cortical thickening, 
cortical destruction, periosteal reaction, bony expansion (Figure 16) and the 
development of a soft tissue mass (Figure 17).14,15,21 Within the long bones, a central 
chondroid lesion which is larger than 5cm is regarded as suspicious for a 
chondrosarcoma (Figure 18).10,15
Computed Tomography is the imaging modality of choice in the assessment of 
endosteal scalloping of chondroid tumours (Figure 19). Furthermore, Computed 
Tomography is particularly useful in the identification of occult matrix mineralization 
which is present in 90%-94% of all chondrosarcomas on CT.10,14,15
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Figure 16: 
Figure 16: Radiograph of a high-grade chondrosarcoma of the proximal femur. 
Anteroposterior radiograph of the proximal femur shows a mixed lytic, sclerotic lesion (large 
arrow) which demonstrates cortical remodelling, cortical thickening and bony expansion 
(small arrow). 
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Figure 17: 
Figure 17: Radiograph of a high-grade chondrosarcoma of the proximal femur.  
Anteroposterior radiograph of the proximal femur shows an ill-defined lesion within the right 
proximal femur which demonstrates extensive chondroid matrix calcification and which 
results in cortical destruction and a pathological fracture of the greater trochanter. There is 
extension of chondroid tissue into the surrounding soft tissue in keeping with an associated 
large soft tissue mass (arrow). 
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Figure 18: 
Figure 18: Radiograph of a low-grade chondrosarcoma of the left proximal humerus.  
Anteroposterior radiograph of the left proximal humerus shows an 10cm in the maximum 
cranio-caudal dimension measuring chondroid lesion in the left proximal humerus (arrow) 
which was a histologically confirmed grade 1 chondrosarcoma. Note the absence of other 
aggressive features such as bone expansion, cortical destruction or periosteal reaction. 
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Figure 19: 
Figure 19: Computed Tomography of a chondrosarcoma of the tibia. Axial CT of the tibia 
exquisitely demonstrates extensive (more than 2/3) endosteal scalloping (arrow).   
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Magnetic Resonance Imaging (MRI) most accurately depicts the intraosseous tumour 
extent, the presence and extent of a soft tissue mass. On MRI, chondrosarcomas 
typically demonstrate a lobulated appearance. The lesion is of low to intermediate 
signal intensity on the T1-weighted images, frequently demonstrates punctate foci 
of signal void due to matrix mineralization and may demonstrate foci of high signal 
intensity on the T1-weighted images which are due to entrapped areas of yellow 
marrow. On the fluid-sensitive sequences, the tumour demonstrates very high signal 
intensity due to the high water content within the chondrocytes (Figure 20a,b). The 
high signal intensity lobules of cartilage cells are frequently separated by septa, 
which are hypointense on the fluid-sensitive sequences and demonstrate 
enhancement after gadolinium administration (Figure 21a,b). Endosteal scalloping, 
soft tissue extension, cortical changes and periosteal reaction are well appreciated 
on MRI (Figure 22a,b). Whilst perilesional bone marrow-like oedema is uncommon, 
its presence favours the diagnosis of a chondrosarcoma (Figure 23a,b).14,34
Accurate preoperative grading of chondrosarcomas is important because the 
treatment of low-grade chondrosarcomas (grade 1 chondrosarcomas) significantly 
differs from that of high-grade chondrosarcomas (grade 2 and grade 3 
chondrosarcomas) in many centres. In many bone tumour centres, low-grade 
chondrosarcomas are treated with curettage whilst high-grade chondrosarcomas are 
treated with en-bloc excision or amputation.35-43
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Figure 20 
Figure 20a:                                                   Figure 20b:  
Figure 20: MRI of a chondrosarcoma of the proximal humerus. Coronal T1W SE MRI (a) and 
coronal T2W FS MRI (b) of the humerus shows an 8.9cm in the maximum cranio-caudal 
dimension measuring lesion in the proximal humeral diaphysis which is of low to 
intermediate signal intensity on the T1-weighted images (a), of high signal intensity on the 
T2 fat-suppressed images (b) and which demonstrates foci of signal void (arrow) due to 
matrix mineralisation. 
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Figure 21 
Figure 21a:                                                    Figure 21b: 
Figure 21: MRI of a chondrosarcoma of the proximal tibia. Coronal T1W SE MRI (a) and 
gadolinium-enhanced T1W MRI (b) of the tibia shows a chondrosarcoma of the proximal tibia 
(a) which demonstrates avid septal enhancement after gadolinium administration (b, arrow). 
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Figure 22 
Figure 22a:         Figure 22b:                                     
Figure 22: MRI of a chondrosarcoma of the proximal femur. Coronal T2W FS MRI (a) and axial 
T2W FS MRI of the left femur shows a 17.1cm in the maximum cranio-caudal dimension 
measuring chondroid lesion with bony expansion (a, arrow), marked endosteal scalloping (b, 
small arrow), cortical thickening and periosteal reaction (b, large arrow). 
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Figure 23: 
Figure 23a:           Figure 23b: 
Figure 23: MRI of a grade 1 chondrosarcoma of the proximal tibia. Sagittal (a) and axial (b) 
PD FS MRI-study of the knee shows an only 2.1cm chondroid lesion within the proximal tibial 
epiphysis. Despite the small size of the lesion, there is extensive peritumoural bone marrow-
like oedema (long arrow), soft tissue oedema and cortical destruction (short arrow). Biopsy 
confirmed a grade 1 chondrosarcoma. 
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Although biopsy is frequently performed prior to surgery, only a small area of the 
tumour is sampled which may result in erroneous down-grading of the tumour. 
Unpublished data from the Royal National Orthopaedic Hospital, Stanmore 
performed by the author of this PhD has shown that CT-guided biopsy of 
chondrosarcomas results in erroneous down-grading of the tumour in approximately 
10% of all cases. More worryingly, a recent study published by Roitman et al., 
demonstrated that concordance between preoperative CT-guided bone biopsy and 
the final pathological grading in chondrosarcomas was 83% in long bones and only 
36% in the pelvis.44
This significant discrepancy between preoperative histological grading and final 
histological grading in chondrosarcomas may result in inadequate treatment of a 
high-grade chondrosarcoma. Although a few studies have attempted to evaluate the 
role of MRI in the differentiation of low-grade from high-grade chondrosarcomas, the 
results of these studies were hampered by small sample size and by the fact that 
these studies only evaluated very few MRI-criteria associated with chondrosarcomas 
leading to conflicting results.45-48 Therefore, there remained uncertainty about the 
role of MRI in the differentiation of low-grade chondrosarcomas from high-grade 
chondrosarcomas. However, the clinical significance of accurate preoperative 
grading of chondrosarcomas can not be overemphasized as erroneous downgrading 
of the tumour due to sampling errors on biopsy may lead to curettage of high-grade 
chondrosarcomas which is inadequate and hence may result in further surgery. In 
chapter 6 of this thesis, I therefore present a study which forms part of this PhD-
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thesis evaluating the utility of MRI in the differentiation of low-grade from high-grade 
chondrosarcomas.  
Fluorodeoxyglucose-positron emission tomography (FDG-PET) is widely used in 
oncological imaging in the detection, diagnosis, staging, treatment response 
assessment and evaluation of recurrence of tumours due to its ability to detect 
glucose uptake in cells with high metabolic activity.49 PET/CT has therefore been 
utilized in an attempt to differentiate benign cartilage tumours from malignant 
cartilage tumours and in the grading of chondrosarcomas. Whilst there is conflicting 
evidence about the role of PET/CT in the differentiation of benign from malignant 
cartilage tumours (Figures 24,25), PET/CT can be used to differentiate benign and 
low-grade malignant cartilage tumours from high-grade malignant cartilage tumours 
as it has been demonstrated that high-grade chondrosarcomas have a higher SUV 
than low-grade chondroid tumours and that the SUV increases with higher 
histological grade of the tumour.16,50 However, this differentiation can be reliably 
made on MRI as demonstrated by our group51 and hence the role of PET/CT in the 
diagnosis and characterization of chondrosarcomas is of doubtful clinical significance 
especially when one considers that MRI forms part of the routine practice in the loco-
regional staging of chondrosarcomas whilst PET/CT is not usually used in the staging 
of chondrosarcomas. Furthermore, in contrast to MRI, PET/CT is associated with a 
radiation burden. Hence, PET/CT plays no significant role in the diagnostic workup of 
patients with chondrosarcoma.  
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Figure 24: 
Figure 24a:   
Figure 24b: 
Figure 24: Eccentric enchondroma of the humeral head. Axial T2W FS MRI-study of the left 
humerus (a) shows imaging features in keeping with an eccentric enchondroma of the 
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humeral head (a, arrow) . On FDG-PET/CT (b), the lesion demonstrates increased FDG-uptake 
with an SUVmax of 3.6. The lesion was a histologically confirmed enchondroma.  
 Figure 25: 
Figure 25a:      Figure 25b: 
Figure 25: Grade 1 chondrosarcoma of the left proximal humerus. Coronal CT (a) shows a 
19cm in the maximum craniocaudal dimension measuring grade 1 chondrosarcoma of the 
left proximal humerus. On FDG-PET/CT (b), the lesion demonstrates mild increased FDG-
uptake with an SUVmax of 3.4. The lesion was a histologically confirmed grade 1 
chondrosarcoma. 
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On 99m-Technitium methylene diphosphonate (MDP) bone scintigraphy, 82% of all 
chondrosarcomas demonstrate marked radio-isotope uptake which is greater than 
the uptake of the anterior iliac crest (Figure 26a,b) whilst avid isotope uptake is only 
observed in 21% of all enchondromas.15 Similarly, a heterogeneous radionuclide 
uptake pattern is observed in 63% of chondrosarcomas but only in 30% of 
enchondromas.15 As the above figures however demonstrate, there is significant 
overlap in the intensity of radio-isotope uptake and the pattern of uptake between 
enchondromas and chondrosarcomas. Therefore, skeletal scintigraphy cannot be 
used to differentiate between the two disease entities. 
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Figure 26 
Figure 26a:  Figure 26b:  
Figure 26: Chondrosarcoma of the proximal femur. Anteroposterior radiograph of the femur 
(a) shows a heavily calcified ill-defined lesion (arrow) in the right proximal femur. On 99m-
Technitium methylene diphosphonate (MDP) bone scintigraphy (b), the lesion demonstrates 
a heterogeneous and avid radio-isotope uptake which is greater than the uptake of the 
anterior iliac crest. The lesion was a histologically confirmed grade 2 chondrosarcoma. 
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1.2.2.6 Staging of chondrosarcomas 
In contrast, skeletal scintigraphy is recommended and therefore widely used in the 
staging of chondrosarcomas at time of presentation to exclude/detect skeletal 
metastases. Similarly, Computed Tomography of the chest is widely recommended 
in the staging of chondrosarcomas to evaluate the presence of pulmonary 
metastases. 52-56 An in depth review of the literature however reveals that this 
recommendation is largely based on evidence acquired from osteosarcomas and 
Ewing sarcomas where skeletal and pulmonary metastases at presentation are 
observed in 4%-19% of all patients.57-62 However, the incidence of skeletal and 
pulmonary metastases in chondrosarcomas at presentation, the role of skeletal 
scintigraphy and Computed Tomography of the chest in the staging of 
chondrosarcomas have not been evaluated previously. In chapter 7, I present a study 
which forms part of the submitted thesis evaluating the role of bone scintigraphy and 
Computed Tomography of the chest in the staging of chondrosarcomas showing 
some intriguing findings.  
1.2.2.7 Management of chondrosarcomas 
In contrast to enchondromas which are only treated if found to be symptomatic, 
chondrosarcomas are always treated with surgery.  This is of particular importance 
in view of the fact that chondrosarcomas are insensitive to radiotherapy or 
chemotherapy and therefore the only hope for cure at present is surgery. The lack of 
67 
non-surgical treatment options is therefore associated with a poor prognosis in 
patients with metastatic chondrosarcoma.  
There has been a change in the surgical treatment technique of low-grade and high-
grade chondrosarcomas in recent years. Whilst previously, both low-and high-grade 
chondrosarcomas were treated with limb-salvage surgery and endoprosthetic 
reconstruction or amputation, low-grade chondrosarcomas are treated in many 
centres with intralesional curettage and local adjuvant therapy. In contrast, high-
grade chondrosarcomas continue to be treated with endoprosthetic reconstruction 
or amputation.36-43,63-66 Therefore, accurate preoperative differentiation of low-
grade chondrosarcomas from high-grade chondrosarcomas is crucial.   
1.2.3 Enchondroma versus low-grade chondrosarcoma 
The differentiation of enchondroma from low-grade chondrosarcoma is one of the 
most difficult topics in musculoskeletal oncology and is challenging for pathologists, 
radiologists and clinicians alike. In the following section, the scientific evidence 
regarding the role and limitation of both histopathology and the various imaging 
modalities in the differentiation of enchondromas from low-grade chondrosarcomas 
is discussed in-depth thereby emphasizing the difficulties in the differentiation of the 
two disease entities.  
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1.2.3.1 Histology 
The difficulties that pathologists face in the distinction of the two disease entities has 
been highlighted in two previous studies which evaluted the interobserver variability 
in the differentiation of enchondromas from low-grade chondrosarcomas and in the 
grading of chondrosarcomas even by experienced musculoskeletal pathologists.67,68
The “Skeletal Lesions Interobserver Correlation among Expert Diagnosticians 
(SLICED) Study Group” quantified the interobserver reliability in the differentiation 
of enchondromas from low-grade chondrosarcomas and in the grading of 
chondrosarcomas among a group of experienced musculoskeletal pathologists and 
radiologists. Nine musculoskeletal pathologists and eight musculoskeletal 
radiologists who were experts in the interpretation of chondroid tumours reviewed 
forty-six cartilaginous tumours of long bone which underwent open biopsy, curettage 
or excision. Both pathologists and radiologists were asked to classify the chondroid 
tumours as benign, low-grade malignant or high-grade-malignant using  whatever 
criteria they use in their daily clinical practice. This study demonstrated that the 
interobserver reliability in the grading of cartilaginous neoplasms in long bones was 
only moderate for pathologists (kappa value=0.443) and only fair for radiologists 
(kappa value=0.345) although the inclusion of Magnetic Resonance Imaging resulted 
in a slightly improved agreement between radiologists (kappa value=0.437).68
Similarly, Eefting and co-workers evaluated the interobserver variability in the 
histological diagnosis of enchondromas from grade 1 chondrosarcomas and in the 
grading of chondrosarcomas. In their study, the authors included 16 chondroid 
tumours which were evaluated by 18 musculoskeletal pathologists. The authors 
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discovered that the distinction between enchondroma and grade 1 chondrosarcoma 
was most  discordant demonstrating only moderate agreement (kappa 
coefficient=0.54) whilst the differentiation between grade 1 and grade 2 
chondrosarcomas demonstrated substantial agreement (kappa coefficient=0.8).67,69
This discrepancy is of significance particularly when comparing these findings with 
the interobserver reliability in the grading observed in other tumours. In contrast to 
this finding for example the interobserver reliability in the histopathological grading 
of soft tissue sarcomas demonstrates kappa coefficients of 0.68 and 0.78.70,71
Similarly, histopathological grading of breast carcinoma has shown similar kappa 
coefficients ranging from 0.69 to 0.73.72-74
The diagnostic dilemma in the differentiation of enchondromas from grade 1 
chondrosarcomas has also been highlighted in multiple publications. In these 
publications central cartilage tumours which on histology are moderately cellular, 
may show focal myxoid change and mild nuclear atypia however fail to demonstrate 
a permeative growth have been variably classified as “CLUMPs” (= cartilaginous 
lesions of unknown malignant potential),24 “grade 0 chondrosarcomas”, “atypical 
enchondromas”25 or as “borderline lesions”. Whilst the diagnostic uncertainty in the 
differentiation of enchondromas from grade 1 chondrosarcomas is widely accepted, 
proven and highlighted in the latest World Health Organization Classification of bone 
tumours published in 2013, the above described terms for low-grade chondroid 
tumours which are difficult to classify  havenot been adpoted in the most recent 
WHO Classification of bone tumours.75 These terms continue to be used in many 
bone tumour centres highlighting the diagnostic dilemma in the differentiation of the 
two disease entities.  
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The reported interobserver variability and diagnostic uncertainty in the distinction of 
enchondromas from grade 1 chondrosarcomas is of clinical relevance as the lack of a 
gold standard in the diagnosis of the two disease entities may result in inappropriate 
surgical treatment of an enchondroma or in lack of treatment of a grade 1 
chondrosarcoma with potentially adverse consequences.68 Furthermore, there is 
controversy regarding the biological behaviour and hence treatment approach of 
these borderline cartilage tumours with some institutions opting for a watch-and-
wait approach24,76 whilst other centres decide to perform intralesional curettage for 
these lesions.25,51,66
Therefore, in the absence of a permeative growth pattern on histology, consensus 
between imaging findings, histopathology and clinical findings is most prudent in the 
distinction of enchondromas from grade 1 chondrosarcomas.10,14 Hence, in the next 
section, the scientific evidence of the role and the limitations of the various imaging 
modalities in the differentiation of enchondromas from low-grade chondrosarcomas 
is discussed. 
The differentiation of enchondromas and grade 1 chondrosarcomas is particularly 
challenging in the long tubular bones such as the femur, tibia and humerus where 
enchondromas are very commonly observed. Similarly, the long tubular bones are 
the most common location for chondrosarcomas accounting for approximately 45% 
of all cases.10
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1.2.3.2 Imaging  
As stated previously, imaging is vital in the differentiation of enchondromas from 
grade 1 chondrosarcomas. In the following section, the role of the various imaging 
modalities in the differentiation of enchondromas from grade 1 chondrosarcomas 
will be discussed in more detail. The imaging modalities discussed below include: 
Radiography, Computed Tomography, Skeletal scintigraphy, Positron Emission 
Tomography and Magnetic Resonance Imaging with a particular emphasis on 
advanced MRI-techniques which include Diffusion-weighted MRI and Dynamic-
contrast enhanced MRI. 
1.2.3.2.1 Radiography 
Geirnaert and co-workers have previously evaluated the role of radiography in the 
differentiation of enchondromas from grade 1 chondrosarcomas. The authors 
included 35 enchondromas and 43 central grade 1 chondrosarcomas. The diagnosis 
of chondroid tumours was based on histology and long-term follow-up. In their study, 
51% of all enchondromas were located in the hands and feet whilst only 5% of all 
grade 1 chondrosarcomas were located in the hands and feet. In contrast, within the 
axial skeleton, grade 1 chondrosarcomas were statistically more commonly observed 
than enchondromas whilst there was no statistically significant difference in the 
number of enchondromas and grade 1 chondrosarcomas identified in the femora and 
humeri. Furthermore, in their study, grade 1 chondrosarcomas were significantly 
larger (median size: 5cm) than enchondromas (median size: 2cm) although there was 
72 
significant overlap in size when enchondromas of the hands and feet were excluded. 
The authors also discovered that only the presence of ill-defined margins and 
lobulated contours on radiography were statistically significant differentiating 
features between enchondromas and grade 1 chondrosarcoma.  The authors 
however reported that radiographic features such as endosteal scalloping, cortical 
thinning, destruction, periosteal reaction and soft tissue extension were not 
statistically significant differentiating features.  The major limitation of this 
publication is however the study design which did not differentiate between the 
radiographic appearances of low-grade chondroid tumours of the hands and feet, 
low-grade chondral tumours of the axial skeleton and low-grade chondroid tumours 
of the long tubular bones. Furthermore, 51% of enchondromas in this study were 
located in the hands and feet whilst 35% of grade 1 chondrosarcomas were located 
in the axial skeleton. The diagnostic challenge in the differentiation of enchondromas 
and grade 1 chondrosarcomas is however largely one centered around the long 
tubular bones (such as the femur, humerus, tibia) because both enchondromas and 
chondrosarcomas are frequently observed in this location particularly as 45% of all 
chondrosarcomas are diagnosed in the long tubular bones.10
Therefore, Murphey and co-workers evaluated the role of radiographs in the 
distinction of enchondromas from chondrosarcomas of the appendicular skeleton. 
The authors included 92 enchondromas and 95 chondrosarcomas which included 35 
grade 1 chondrosarcomas (37% of all chondrosarcomas), 29 grade 2 
chondrosarcomas (31% of all chondrosarcomas) and 31 grade 3 chondrosarcomas 
(33% of all chondrosarcomas). They found that a depth of endosteal scalloping of 
more than two-third of the cortical thickness as well as the extent of endosteal 
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scalloping were statistically significant differentiating features on radiography. 
Furthermore, increased tumour size, the presence of cortical destruction, cortical 
thickening, pathological fracture, periosteal reaction and soft tissue extension were 
statistically significant differentiating features favouring the diagnosis of a 
chondrosarcoma.  A major limitation of this study is that the study cohort included 
chondrosarcomas in general and did not differentiate between low-grade and high-
grade chondrosarcomas in their analysis. It is well established that both the 
histological and imaging differentiation of enchondromas from high-grade 
chondrosarcomas does not represent a diagnostic challenge. In contrast, the 
difficulty lies in the differentiation of enchondromas from low-grade 
chondrosarcomas. Therefore, the results published by Murphey et al. have to be 
interpreted in the context of this significant limitation and it cannot be assumed that 
the described differentiating features are also applicable in the differentiation of 
enchondromas from low-grade chondrosarcomas of the appendicular skeleton.15
1.2.3.2.2 Computed Tomography 
In the above quoted publication by Murphey et al., the authors also evaluated the 
role of CT in the differentiation of enchondromas and chondrosarcomas of the 
appendicular skeleton. In their study, the authors analyzed the CT-examinations of 
88 lesions of which 39 were enchondromas and 49 lesions were chondrosarcomas. 
On CT, the size of the lesion, depth and extent of endosteal scalloping, cortical 
destruction, the presence of a pathological fracture, periosteal reaction, and soft 
tissue extension were statistically significant differentiating features. In contrast, 
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cortical remodeling, cortical thickening, the presence and extent of matrix 
calcification as well as the attenuation values of the non-mineralized component on 
CT were not statistically significant. As stated above, the major limitation of this study 
is the lack of differentiation of enchondromas from low-grade chondrosarcomas.15
1.2.3.2.3 Skeletal Scintigraphy 
The role of skeletal scintigraphy in the differentiation of enchondromas from 
chondrosarcomas in the appendicular skeleton has also been assessed by Murphey 
and co-workers. The authors retrospectively reviewed the skeletal scintigraphs of 67 
enchondromas and 51 chondrosarcomas. Isotope uptake in the lesions was graded 
on a scale of 1-3. Grade 1 was classified as uptake within the lesion less than that of 
the anterior iliac crest, grade 2 was similar to the uptake in the anterior iliac crest 
whilst grade 3 was defined as uptake greater than in the anterior iliac crest. 
Furthermore, the authors assessed if the radio-isotope in the lesions was 
homogeneous or heterogeneous.  The authors found that bone scintigraphy showed 
greater isotope uptake when compared to the anterior iliac crest in 82% of 
chondrosarcomas (figure 26) whilst this finding was only observed in 21% of all 
enchondromas (figure 8). In contrast, 79% of all enchondromas demonstrated equal 
or lower activity than the anterior iliac crest (figure 7b). Similarly, heterogeneous 
uptake was observed in 63% of all chondrosarcomas but only in 30% of all 
enchondromas. This finding was thought to be due to increased biological activity of 
chondrosarcomas.15 Although the difference in radio-isotope uptake between 
enchondromas and chondrosarcomas of the appendicular skeleton was statistically 
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significant in this study, the authors as stated above did not differentiate between 
enchondromas and grade 1 chondrosarcomas and therefore these findings cannot 
be used to differentiate between the two disease entities. 
1.2.3.2.4 Positron emission tomography  
The potential role of FDG PET in the differentiation of benign cartilaginous tumours 
and chondrosarcomas has been assessed in three studies.  
Aoki et al. studied the SUV values in four enchondromas, one osteochondroma and 
six chondrosarcomas which included one grade 1 chondrosarcoma, four grade 2 
chondrosarcomas and one grade 3 chondrosarcoma. They found that the mean SUV 
in benign cartilage tumours was 0.96 whilst the mean SUV of chondrosarcomas was 
2.23. However, the sample size of the study was very small and included only one 
grade 1 chondrosarcoma. Therefore, the findings cannot be used to differentiate 
enchondromas from low-grade chondrosarcomas.77
Similarly, Feldman et al. also studied the role of PET in 29 chondroid tumours. In this 
study, the benign chondroid tumour group included 11 enchondromas and 7 
osteochondromas whilst the chondrosarcoma-group included 5 grade 1 
chondrosarcomas, 2 grade 2 chondrosarcomas, 1 grade 3 chondrosarcoma and 2 
dedifferentiated chondrosarcomas. The authors found that a cut-off maximum SUV 
of 2.0 resulted in a sensitivity of 90.9%, a specificity of 100% and a diagnostic accuracy 
of 96.6% in the differentiation of benign cartilage tumours from chondrosarcomas. 
In view of the heterogeneity of benign cartilage tumours which were included in this 
study and in view of the inclusion of low-grade and high-grade chondrosarcomas, no 
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conclusions about the role of PET in the differentiation of enchondromas from low-
grade chondrosarcomas can be made based on this study.50
In contrast, a study by Lee and co-workers retrospectively assessed PET in 35 
cartilaginous tumours which included ten enchondromas, three osteochondromas, 
twelve grade 1 chondrosarcomas, five grade 2 chondrosarcomas and five grade 3 
chondrosarcomas. In this study, the mean SUV of benign chondral tumours was 
1.147, the mean SUV of grade 1 chondrosarcomas was 0.898 whilst the mean SUV of 
high-grade chondrosarcomas was 6.903. The authors therefore concluded that 
although PET could be used to differentiate low-grade chondrosarcomas from high-
grade chondrosarcomas, it could not distinguish between benign cartilage tumours 
and grade 1 chondrosarcomas (Figures 24, 25).  Hence, there is no role for PET in the 
differentiation of enchondromas from low-grade chondrosarcomas.16
1.2.3.2.5 Magnetic Resonance Imaging  
The utility of MRI in the differentiation of enchondromas from chondrosarcomas has 
been investigated in a few studies. In the following section, the role of anatomical 
MRI in the differentiation of the two disease entities will be discussed followed by a 
review of the literature on the role of functional MRI (dynamic-contrast enhanced 
MRI and diffusion-weighted MRI) in the distinction of enchondromas from low-grade 
chondrosarcomas.  
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1.2.3.2.5.1 Anatomical Magnetic Resonance Imaging 
Murphey et al. retrospectively analyzed the MR Imaging of 35 enchondromas and 33 
chondrosarcomas of the appendicular skeleton.  They evaluated lesion size, 
endosteal scalloping, cortical remodeling, cortical destruction, pathological fracture, 
periosteal reaction, cortical thickening and soft tissue extension. The group found 
that the mean length of enchondromas was 5cm whilst the mean length of 
chondrosarcomas was 8cm. Similarly, the depth and extent of endosteal scalloping 
was significantly different in enchondromas and chondrosarcomas with endosteal 
scalloping of more than two-thirds being observed in 67% of chondrosarcomas but 
only in 11% of enchondromas. Furthermore, cortical remodeling, cortical 
destruction, soft tissue extension and pathological fracture were statistically 
significant differentiating features between enchondromas and chondrosarcomas 
whilst cortical thickening and periosteal reaction could not differentiate between the 
two disease entities. However, a significant limitation of this study is that the authors 
did not perform a subgroup analysis to evaluate potential differentiating MRI-
features between enchondromas and low-grade chondrosarcomas.15
There have been two studies which evaluated the role of MRI in the differentiation 
of enchondromas from low-grade chondrosarcomas. Ferrer-Santacreu et al. assessed 
the role of MRI in the differentiation of enchondromas and low-grade 
chondrosarcomas of the appendicular skeleton in 82 patients. The authors found no 
statistically significant differentiating imaging features between enchondromas and 
low-grade chondrosarcomas.78
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Another study by Choi et al. assessed the MRI-features in 16 enchondromas and in 
18 low-grade chondrosarcomas. In contrast to Ferrer-Santacreu, the authors found 
that predominantly intermediate signal intensity on T1WI, a multilobular appearance 
on contrast-enhanced T1WI, cortical destruction, soft tissue extension, surrounding 
bone marrow oedema, abnormal soft tissue signal, epiphyseal involvement and 
location in the flat bone were more commonly observed in low-grade 
chondrosarcomas than in enchondromas. A significant limitation of this publication 
is that the authors included chondrosarcomas of the flat bones and enchondromas 
of the hand in their study. As previously stated, the differentiation of enchondromas 
from low-grade chondrosarcomas does not represent a diagnostic challenge in these 
locations. Similarly, the imaging findings of chondroid lesions of the hands and pelvis 
are very different to the imaging findings of chondroid lesions of the appendicular 
system. Therefore, the role of conventional MRI in the differentiation of 
enchondromas from low-grade chondrosarcomas remained uncertain until very 
recently.79 A recent study by the author of this thesis specifically evaluated the role 
of conventional MRI, DCE-MRI and clinical findings in the differentiation of 
enchondromas from low-grade chondrosarcomas of long bones (see Appendix 1). In 
this study, we retrospectively analyzed the MRI-findings in 60 central chondroid 
tumours which included 27 enchondromas, 10 cartilaginous tumours of unknown 
malignant potential, 15 grade 1 chondrosarcomas and 8 high-grade 
chondrosarcomas. The subgroup analysis which evaluated the conventional MRI-
findings of enchondromas and grade 1 chondrosarcomas, revealed that more than 
2/3 endosteal scalloping demonstrated a sensitivity of 71.4% (95% confidence 
intervals: 41.9%-91.6%) and a specificity of 92.9% (95% confidence interval: 76.5%-
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99.2%), bone expansion showed a sensitivity of 50% (95% confidence interval: 23%-
77%) and a specificity of 89.3% (95% confidence interval: 71.8%-97.7%), cortical 
destruction showed a sensitivity of 35.7% (95% confidence interval: 12.8%-64.9%) 
and a specificity of 100% (95% confidence interval: 87.7%-100%) whilst the presence 
of a soft tissue mass revealed a sensitivity of 40% (95% confidence interval: 16.3%-
67.7%) and a specificity of 100% (95% confidence interval: 87.2%-100%). Of note is 
that the presence of pain attributed to the lesion resulted in a sensitivity of 60% (95% 
confidence interval: 32.3%-83.7%) and a specificity of 88.9% (95% confidence 
interval: 70.8%-97.7%) in the differentiation of enchondromas from grade 1 
chondrosarcomas. Subsequent calculation of Odds ratios showed an Odds ratio for 
pain attributable to the lesion of 12 (95% confidence interval: 2.5-58.5), an Odds ratio 
for more than 2/3 endosteal scalloping of 25 (95% confidence interval: 4.2-15.7), and 
an Odds ratio for bone expansion of 14.3 (95% confidence interval: 2.5-83.1) whilst 
cortical destruction and the presence of a soft tissue mass were diagnostic for a grade 
1 chondrosarcoma. Of note is that the 95% confidence intervals for the sensitivity, 
specificity and the Odds ratios were wide. This finding is most likely due to the small 
sample size of the study. Despite the wide confidence intervals of the results, the 
study demonstrated a positive relationship between pain attributable to the lesion, 
more than 2/3 endosteal scalloping, bone expansion and the diagnosis of a grade 1 
chondrosarcoma. Although the study confirmed that cortical destruction and the 
presence of a soft tissue mass are diagnostic for a grade 1 chondrosarcoma, these 
findings are not commonly observed in grade 1 chondrosarcomas. However, the 
study demonstrated that more than 2/3 of endosteal scalloping is the most sensitive 
conventional MRI sign of grade 1 chondrosarcomas. Similarly, pain attributed to the 
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lesion was an important clinical sign of grade 1 chondrosarcomas highlighting the 
importance of a close collaboration between radiologists, clinicians and pathologists 
in order to differentiate between enchondromas from grade 1 chondrosarcomas.80
1.2.3.2.5.2 Dynamic Contrast-Enhanced Magnetic Resonance Imaging 
Dynamic contrast-enhanced MRI (DCE-MRI) is a functional MRI-technique which 
allows the non-invasive assessment of tumour vascularity.81 DCE-MRI has previously 
been utilized in an attempt to differentiate benign bone tumours from malignant 
bone tumours.82 More specifically, there have been three studies which attempted 
to differentiate benign chondroid tumours from chondrosarcomas using DCE-
MRI.83,84
Geirnaerdt and co-workers assessed eight enchondromas, eleven osteochondromas 
and eighteen chondrosarcomas which included seven grade 1 chondrosarcomas, 
nine grade 2 chondrosarcomas and two grade 3 chondrosarcomas using DCE-MRI in 
an attempt to differentiate benign cartilage tumours from chondrosarcomas. The 
authors evaluated the start of contrast uptake (early versus delayed) and the 
progression of contrast uptake (exponential versus gradual) within chondroid 
tumours. They found that early enhancement was observed in 89% of all 
chondrosarcomas but not in enchondromas whilst delayed enhancement was seen 
in 11% of chondrosarcomas and in 38% of enchondromas. In contrast, no 
enhancement was described in 63% of all enchondromas but in no case of a 
chondrosarcoma. Furthermore, exponential uptake was seen in 61% of all 
chondrosarcomas but not in enchondromas whilst gradual enhancement was 
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observed in 38% of enchondromas and in 39% of chondrosarcomas. The authors 
therefore concluded that lack of enhancement within a cartilage tumour excluded a 
chondrosarcoma. Furthermore, they concluded that the differentiation of benign 
cartilage tumours from chondrosarcomas was possible with a sensitivity of 61%, a 
specificity of 95%, a positive predictive value of 92% and a negative predictive value 
of 72%. A significant limitation of this study is that the authors assessed the contrast 
uptake pattern in enchondromas versus chondrosarcomas in general and did not 
perform a subgroup analysis evaluating the contrast uptake pattern in 
enchondromas versus low-grade chondrosarcomas.84 As stated previously, the 
distinction between enchondromas and high-grade chondrosarcomas does not 
represent a diagnostic challenge.10 A further limitation of this study is the small 
sample size which most likely would have hampered a subgroup analysis.  
De Coninck et al. also evaluated the role of DCE in the differentiation of 
enchondromas from chondrosarcomas. In their retrospective study, the authors 
included 75 enchondromas and 31 chondrosarcomas which included 18 low-grade 
chondrosarcomas, 10 intermediate grade chondrosarcomas and 3 high grade 
chondrosarcomas. The authors found that enhancement within the tumour which 
was two times more when compared to muscle combined with a 76 degree slope of 
the uptake curve resulted in a 100% sensitivity and 63.3% specificity in the detection 
of chondrosarcomas. A significant limitation of this study is the inclusion of low-grade 
and high-grade chondrosarcomas and the fact that the authors did not differentiate 
between low-grade chondrosarcomas from high-grade chondrosarcomas in this 
study. Therefore, the obtained results cannot be utilized in the differentiation of 
enchondromas from low-grade chondrosarcomas.83 Hence, the role of DCE-MRI in 
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the differentiation of the two disease entities remained unclear until very recently. 
As stated above, the author of this thesis re-evaluated the role of conventional MRI, 
DCE-MRI and clinical assessment in the differentiation of enchondromas from low-
grade chondrosarcomas and high-grade chondrosarcomas of long bone (see 
Appendix 1). In this study, we evaluated the median angle of the curve, the median 
absolute enhancement of the curve and the relative enhancement of the curve for 
enchondroma, CLUMPs,  grade 1 chondrosarcoma and high-grade chondrosarcomas. 
Whilst the study demonstrated a statistically significant difference in the median 
angle of the curve this was due to differences in the angle of the curve between 
enchondromas versus high-grade chondrosarcomas, due to differences in the angle 
of the curve between the CLUMP-group and grade 1 chondrosarcomas and due to 
differences in the group between the CLUMP-group and the high-grade 
chondrosarcoma group. Similarly, the statistically significant difference in the median 
absolute enhancement of the various curves was due to differences in the absolute 
enhancement of enchondromas versus high-grade chondrosarcomas and due to 
differences between the CLUMP-group and high-grade chondrosarcoma group. In 
contrast, there was no statistically significant difference in the pairwise comparison 
between the various chondroid groups. Similarly, there was no statistically significant 
difference of the various DCE-MRI parameters between enchondromas and grade 1 
chondrosarcomas. This study therefore demonstrates that the previously reported 
potential role of DCE-MRI in the differentiation of enchondromas from 
chondrosarcomas is most likely due to the inclusion of high-grade chondrosarcomas. 
In contrast, according to our findings, DCE-MRI cannot be utilized to differentiate 
enchondromas from low-grade chondrosarcomas.80
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1.2.3.2.5.3 Diffusion-Weighted Magnetic Resonance Imaging (DWI) 
Another functional MRI-technique which has gained increased popularity and is a 
promising tool in the diagnosis and treatment response assessment in oncological 
imaging is diffusion-weighted MRI (DWI). DWI exploits the principle of Brownian 
motion of water molecules. Within biological tissues, the motion of water molecules 
is restricted by barriers such as large molecules and cell membranes. The degree of 
diffusion restriction of water molecules in biological tissue is inversely correlated to 
tissue cellularity and the integrity of cell membranes. Hence, high cellular tissue may 
demonstrate more restricted diffusion than low cellular tissue.85,86 DWI has therefore 
been utilized to differentiate benign skeletal lesions from malignant skeletal 
lesions.87,88 As one differentiating feature between enchondromas from low-grade 
chondrosarcomas on histology is cellularity, DWI appears to be an attractive 
functional imaging technique in the differentiation of the two disease entities. There 
has been a paucity of evidence in the literature about the potential role of DWI in the 
differentiation of enchondromas from low-grade chondrosarcomas.  
A recent study assessed the utility of DWI in the differentiation of enchondromas 
from chondrosarcomas. The authors found that the ADC-values between 
enchondromas, grade 1, grade 2 and grade 3 chondrosarcomas were statistically 
significant, however the differences were only small and the authors therefore 
concluded that a larger sample size was required to assess the utility of DWI in the 
differentiation of enchondromas from grade 1 chondrosarcomas.89 In the fifth 
chapter of this thesis, the author therefore presents a study evaluating the role of 
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DWI in the differentiation of enchondromas from low-grade chondrosarcomas which 
showed some interesting findings. 
Whilst it has become evident from the extensive review of the literature, that 
imaging plays a role in the diagnosis of central chondroid bone tumours, there 
remains uncertainty about the role that imaging may play in advancing the 
understanding of the pathogenesis of enchondromas and in the precise role that 
imaging may play in the diagnosis, grading and staging of chondrosarcomas of bone. 
In the following chapters, the authors’ published work submitted for consideration 
of a PhD therefore investigates the theory that imaging may aid in the understanding 
of the pathogenesis of enchondromas and may aid in the diagnosis, grading and 
staging of chondrosarcomas of bone. 
The first two chapters are review articles which summarize the role of imaging in the 
diagnosis of enchondromas and chondrosarcomas. The third article investigates the 
role that MRI may play in advancing the understanding of the pathogenesis of 
enchondromas. The fourth article assesses the role of DWI-MRI as a functional MRI-
technique in the differentiation of enchondromas from low-grade chondrosarcomas. 
The fifth article evaluates the utility of conventional MRI in the grading of 
chondrosarcomas of long bone. Finally, the sixth article examines the role of bone 
scintigraphy and Computed Tomography of the chest in the staging of 
chondrosarcomas. The presented thesis therefore investigates the role of imaging in 
the diagnosis, grading and staging of chondrosarcomas.  
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Chapter 8: Discussion  
8.1 Summary 
Enchondromas are the second most common benign cartilage tumour whilst 
chondrosarcomas are the second most common malignant primary bone tumour 
after osteosarcoma. Despite this, there has been a paucity of evidence about the role 
of imaging in the diagnosis, grading and staging of chondrosarcomas. The hereby 
presented portfolio of peer-reviewed published work submitted for consideration of 
a PhD thesis significantly enhances the understanding of the pathogenesis of 
enchondromas and significantly contributes to the knowledge about the role of 
imaging in the diagnosis, grading and staging of chondrosarcomas. 
The first two articles, which form part of the thesis are review articles providing an 
overview of imaging of benign chondroid tumours and chondrosarcomas. In these 
articles, the role of imaging in the diagnosis of benign chondroid tumours and 
chondrosarcomas, in the grading and staging of chondrosarcomas is discussed.  
The third article, which is an original article, critically appraises the commonly held 
belief about the pathogenesis of enchondromas. Whilst it is widely believed that 
enchondromas arise from cartilage remnants which have been displaced from the 
growth plate during the process of skeletal maturation, the origin of this very theory 
has been forgotten in modern medicine. Furthermore, this theory remains unproven. 
In the original article entitled “Can MR imaging challenge the commonly accepted 
theory of the pathogenesis of solitary enchondroma of long bone?”, we have 
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investigated the origin of the above stated theory and  have surprisingly discovered 
that this theory was first postulated by the “father of modern pathology” Rudolf 
Virchow in 1863 in his 3-volume book “Die krankhaften Geschwülste” and later 
expanded upon by Virchow in the article “Über die Entstehung des Enchondroma und 
seine Beziehungen zu der Ecchondrosis und der Exostosis cartilaginea” which he 
published in “Monatsberichte der Königlich Preussischen Akademie der 
Wissenschaften” in 1875. Furthermore, we discovered after studying the original 
manuscripts in German, that Virchow’s theory was based on observations he made 
in patients suffering from rickets (Figure 27).90,91 Until our publication, both the origin 
and historic background of this theory were unknown in modern medicine. The re-
discovery of the very origin, background and reasoning of this theory in our article is 
therefore a significant contribution to the history of medicine in general and the 
understanding of the history of the pathogenesis of enchondromas in particular.  
We subsequently challenged this theory using MR Imaging in skeletally immature 
patients.  The article which forms part of the thesis, raises doubts about the widely 
believed but unproven theory that enchondromas arise from displaced cartilage 
islands during the process of skeletal maturation as we did not identify any 
macroscopically detectable cartilage islands on MRI. The doubt about the validity of 
this theory is also supported by the discovery of mutations in the genes encoding 
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) in enchondromas, periosteal 
chondromas and central chondrosarcomas therefore highlighting their role in the 
tumourigenesis of enchondromas.33 There are limitations to our study. Our 
investigations and study do not refute the theory that enchondromas arise from 
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cartilage remnants which have been displaced from the growth plate during the 
process of skeletal maturation. The study raises doubts about the validity of this 
theory for the following reasons:  
Firstly, Virchow based his theory on observations he made in pathology specimen of 
children with rickets where he observed proliferations and islands of cartilage 
extending from the growth plate into the metadiaphysis. He therefore concluded 
that such foci of cartilage proliferation could have persisted into adulthood and 
would have subsequently formed into enchondromas. Whilst rickets was endemic in 
Europe of the 19th century, its incidence although slightly increasing lately, has 
dramatically reduced since the 19h century and can therefore not be an important 
cause for the development of enchondromas. Other causes, which could result in 
disruption of the growth plate, cannot be ruled out as potential causative agents in 
the pathogenesis of enchondromas. In particular, trauma in the skeletally immature 
individual, continues to be frequently observed and remains a possible cause for the 
development of enchondromas. This is of particular importance when one considers 
that repetitive injuries as seen in elite athletes or single event insults such as 
fractures, may lead to injury and disruption of the growth plate and on MRI may 
manifest themselves as extension of physeal cartilage into the metaphysis.92-98
Similar extensions of cartilage from the growth plate into the metaphysis were 
observed in seven MRI-examinations of six patients in our studied cohort (2.9% of all 
cases). In all seven MRI-studies, the cartilage extensions into the growth plate were 
in continuity with the growth plate. The aetiology of these cartilage extensions in our 
study remains unknown due to the retrospective nature of the study. We can 
152 
therefore not exclude that such cartilage extensions may become separated from the 
growth plate at a later stage during the process of skeletal maturation and could 
potentially develop into enchondromas. This is of importance especially when one 
considers that growth plate closure is usually observed at the age of 16 years and the 
median age of patients in our study was 13 years. 99 However, as stated above, similar 
cartilage extensions have been described previously and have been attributed to 
single event or multi event injuries such as previous trauma which either regress after 
cessation of the repetitive injury or in the case of severe injuries may lead to 
significant clinically evident growth disturbances.94,96
Furthermore, we did not identify any enchondromas in our cohort which evaluated 
240 MRI-studies of the knee in 209 skeletally immature patients. The absence of 
enchondromas in skeletally immature patients in our study is however in contrast to 
the prevalence of incidental enchondromas on MRI-examinations of the knee in 
adults which has been quoted to be 2.8-2.9%.  6,100 Our study therefore also highlights 
the rarity of enchondromas in skeletally immature individuals which is in contrast to 
adults where enchondromas are frequently observed.  
We cannot exclude that some of the patients in our study could potentially develop 
displacement of cartilage islands into the growth plate in the future or may have 
developed displacement of cartilage islands not depicted on conventional MRI. 
Hence, the presented study does not refute the above stated theory. Our study 
findings and the investigation and subsequent rediscovery of the very origin of the 
theory justifies raising doubts about the validity of the widely believed but unproven 
theory. Furthermore, the discovery that a majority of enchondromas are associated 
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with mutations in the genes IDH1 and IDH2 strongly favours that enchondromas are 
neoplastic lesions rather than developmental abnormalities.33
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Figure 27:  
155 
Figure 27 (Illustrations taken from the article: “Über die Entstehung des Enchondroma und 
seine Beziehungen zu der Ecchondrosis und der Exostosis cartilaginea” published in 
“Monatsberichte der Königlich Preussischen Akademie der Wissenschaften” in 1875 by R. 
Virchow) 
In figure 27.1 Virchow uses an image of pathology specimen in a child with rickets of the 
distal femur to demonstrate proliferation of cartilage of the growth plate with islands of 
cartilage which have “separated completely and lie backwards within the fully developed 
spongiosa” (translated from German into English by me).   
In figure 27.2 Virchow shows an image of a pathology specimen in a child with rickets of the 
distal femur to demonstrate “a large and a smaller completely separated island of 
proliferating cartilage which lies within the spongiosa” (translated from German into English 
by me).   
In figure 27.3 Virchow demonstrates an image of a pathology specimen of a skeletally mature 
patient with an enchondroma of the distal femur. In his publication, he states that the 
location of the enchondroma “correlates so precisely with the location of the islands of 
cartilage observed in the skeletally immature bones (of figure 27.1 and 27.2) that one cannot 
have any doubt, that such a remnant of cartilage really persisted (into adulthood)” 
(translated from German into English by me).   
156 
The diagnosis and grading of chondrosarcomas represent major challenges for 
pathologists, clinicians and radiologists alike. Particularly, the differentiation of 
enchondromas from low-grade chondrosarcomas is one of the most difficult and 
controversial diagnostic dilemmas in musculoskeletal oncology. Whilst anatomical 
MRI has been used in attempt to differentiate between the two disease entities, 
there remains considerable uncertainty in the diagnosis.  
In the fourth article (original article), we have attempted to use diffusion-weighted 
MRI (DWI), - a non-invasive functional MRI-technique which indirectly assesses the 
cellularity of biologic tissues - in an attempt to differentiate enchondromas from 
chondrosarcomas. A previous retrospective study stated that DWI might be 
promising in the differentiation of enchondromas from low-grade chondrosarcomas. 
However, the results of this study were hampered by a small sample size which 
included only 14 central chondroid tumours. In this study, the authors measured 
mean ADC-values in three consecutive slices and correlated the mean ADC-values 
with the histological grading of the chondroid tumours. Whilst the authors found a 
statistically significant difference in the ADC-values of enchondromas from 
chondrosarcomas, they concluded that there was only a slight difference in the ADC-
values of enchondromas from chondrosarcomas and therefore a significantly larger 
patient cohort was required to evaluate the role that DWI may play in the 
differentiation of enchondromas from chondrosarcomas and low-grade 
chondrosarcomas in particular.89
The aim of our study was therefore to investigate the potential role that DWI could 
play in the differentiation of enchondromas from chondrosarcomas in general and in 
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the differentiation of enchondromas from low-grade chondrosarcomas in a larger 
patient cohort. In the fourth article, which forms part of this PhD-thesis, we therefore 
re-assessed the role of DWI in the differentiation of enchondromas from 
chondrosarcomas in a larger patient cohort. We included 52 central chondroid bone 
tumours of which there 24 enchondromas, 5 cartilaginous lesions of unknown 
malignant potential, 15 grade 1 chondrosarcomas, three grade 2 chondrosarcomas, 
two grade 3 chondrosarcomas and three dedifferentiated chondrosarcomas. We 
found that there was a statistically significant difference in the mean and minimum 
ADC values in all groups. Post hoc analysis demonstrated that this difference in mean 
and minimum ADC values was due to the ADC values in the dedifferentiated 
chondrosarcoma group. In contrast, the mean and minimum ADC-values of low-
grade chondroid tumours and high-grade chondrosarcomas were not statistically 
significantly different. We therefore concluded that DWI could not differentiate 
between enchondromas and chondrosarcomas and that it does not aid in the 
distinction of low-grade chondroid tumours from high-grade chondrosarcomas. This 
study which forms part of the portfolio of publications submitted for consideration 
of a PhD therefore significantly advances the understanding about the role of 
Diffusion-weighted MRI in the differentiation of enchondromas from 
chondrosarcomas. 
There are several limitations to our study.  
Firstly, the retrospective nature of the study and the fact that the study was 
performed in a bone tumour centre most likely has resulted in a selection bias as 
many enchondromas observed on routine MRI-examinations are not referred to a 
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bone tumour centre where the study was performed. Secondly, whilst 81% of all 
central cartilage tumours were histologically confirmed, ten enchondromas did not 
undergo histological confirmation representing 19% of all central cartilaginous 
tumours and 42 % of all enchondromas in our study. We have applied stringent 
criteria for designating a lesion as an enchondroma based on widely accepted 
imaging features.  
Thirdly, minimum and mean ADC values were measured in one slice.  This slice was 
carefully selected to correspond with the slice on conventional MR imaging, which 
showed the most aggressive imaging features. Furthermore, there is no standardised 
technique in the literature which has been widely accepted for analysis of DWI-data. 
Whilst some authors have analysed DWI-data using a whole-tumour volume 
approach,101-104 analysis of DWI data using the region of interest approach continues 
to be most widely performed technique similar to the analysis method used in our 
publication.87,88,105-109 110,111 Although analysis of skeletal lesions using a whole tumour 
volume approach is likely to be more accurate taking into consideration 
heterogeneity of ADC-values within skeletal lesions, this technique is very time-
consuming, not widely performed and very difficult to implement in routine clinical 
practice due to its impracticality and time-consuming nature. Thus, the aim of our 
data analysis was to investigate an analysis method which could be easily 
implemented in routine clinical practice and hence if found to be useful could be 
widely adopted. Whilst there have been no studies which compared the different 
analysis methods of DWI in bone tumours, there has been a very recent study which 
evaluated the interobserver variability of three selective region-of-interest 
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measurement protocols for apparent diffusion coefficient quantifications in soft 
tissue tumours and compared them with whole tumour volume ADC measurements. 
The authors found that whilst all selective and whole tumour volume measurements 
offered good to excellent interobserver agreement, the selective observer based 
method of ADC measurement resulted in the closest values to whole tumour volume 
measurements. The authors therefore concluded that a simplified observer-based 
manual method of ADC quantification in the evaluation of soft tissue tumours was 
comparable to whole tumour volume measurements of the minimum and mean 
ADCs, and required significantly less analysis time.112 Further research is required to 
evaluate which analysis method in bone tumours and skeletal lesions are most 
feasible and accurate in the interpretation of ADC-values in daily clinical practice. This 
is of importance if DWI is to be implemented as a routine MRI-sequence in daily 
clinical practice.  
Furthermore, the inter-observer reliability of measurement of ADC-values has not 
been tested in this article because both the slice selection and the measurement of 
ADC-values was performed by one reader only. Therefore, the reliability of the study 
remains untested. Lastly, we did not calculate 95% confidence intervals for the 
minimum and mean ADC-values. However, the measured sample mean values in the 
study may not reflect the population mean values. Therefore, the range of ADC 
values which contain the true population mean with 95% certainty cannot be 
quantified based on the study results provided.  
The fifth article (original article) presented as part of the submitted PhD-thesis 
represents an original article which evaluates the role of MRI in the grading of 
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chondrosarcomas. Whilst a previous publication showed that the presence of a soft 
tissue mass favoured the diagnosis of a high-grade chondrosarcoma, the utility of this 
study was hampered by the fact that the authors only assessed a few MRI-features 
which are associated with chondrosarcomas and by the small sample size of the 
study.48 Therefore, there remained uncertainty about the role of other MR Imaging 
features in the differentiation of high-grade from low-grade appendicular 
chondrosarcomas. Hence, we evaluated a wide range of MRI-features, which are 
used in the characterization of chondrosarcomas representing the largest study 
published on this topic. In this retrospective study, we analysed the MRI-
examinations of 179 chondrosarcomas of long bones and divided them into low-
grade chondroid lesions and high-grade chondrosarcomas. We found that on 
multivariate analysis, bone expansion, active periostitis, the presence of a soft tissue 
mass, and tumour length are statistically significant differentiating factors between 
low-grade and high-grade chondroid tumours. On logistic regression analysis, the 
Odds ratio for bone expansion, active periostitis, soft tissue mass and tumour length 
were: 8.8 (95% confidence interval 2.4-32.4), 52.8 (5-562.2), 21.1 (4-111.1) and 1.4 
(1.2-1.7) for the diagnosis of a high-grade chondrosarcoma. The above stated figures 
in the study demonstrate wide confidence intervals for all four MRI-features which 
could be due to the variation of MRI-features in the high-grade chondrosarcoma 
group although the sample size albeit large in our study could also be a contributing 
factor. However, it is important to note that the study demonstrated a positive 
relationship between the above described MRI features and the diagnosis of a high-
grade chondrosarcoma. Our study also demonstrated that the presence of the above 
described four MRI features showed a diagnostic accuracy of 95.6%. We therefore 
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concluded that these imaging features accurately predicted the presence of a high-
grade chondrosarcoma. Thus, MRI can be used accurately to differentiate low-grade 
chondroid tumours from high-grade chondrosarcomas of the major long bones which 
in turn may avoid inadequate surgery. This is of particular clinical importance when 
one considers that biopsy may result in sampling errors of chondrosarcoma of long 
bone of up to 17% and hence may result in inappropriate treatment.44
There are nevertheless limitations to our study.  
Firstly, due to the retrospective nature of our study, the MRI protocol was not 
standardised. In view of the rarity of chondrosarcomas, there have been no 
prospective studies evaluating the role of MRI in the diagnosis and grading of 
chondrosarcomas. Furthermore, our article continues to be one of the largest studies 
evaluating the role of MRI in chondrosarcoma hence highlighting challenges faced in 
the development and conduct of potential prospective studies which would require 
inclusion of a large patient cohort in order to evaluate MRI-features in the 
differentiation of low-grade from high-grade chondrosarcomas.  
Secondly, our study included a higher number of high-grade chondrosarcomas than 
is usually observed in other series which was most likely due to the tertiary nature of 
the institution in which the study was conducted. This may therefore have led to a 
selection bias.  
Thirdly, the differentiation of enchondromas from low-grade chondrosarcomas 
demonstrate a low reliability even among subspecialised histopathologists due to the 
lack of a gold standard in the distinction of the two disease entities.67,68 The difficulty 
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that radiologists, pathologists and clinicians face in the differentiation of 
enchondromas from low-grade chondrosarcomas was also reflected in our study by 
the fact that our study included 28 “borderline malignant chondroid lesions” which 
were classified as grade 0.5 chondrosarcomas. All chondral tumours at the institution 
in which the study was performed were reviewed by two musculoskeletal 
pathologists and the diagnosis of benign versus malignant chondral tumours was 
made in consensus with radiologists, pathologists and clinicians. Furthermore, the 
author of this thesis performed an unpublished analysis at the time when the original 
analysis was performed which excluded the above stated 28 “borderline malignant 
chondroid lesions” or CLUMPs. The results of this analysis demonstrated that on 
multivariate analysis, bone expansion, active periostitis, soft tissue mass and tumour 
length continued to be statistically significant differentiating factors whilst the other 
MRI-features continued to be not statistically significant. Therefore, the inclusion of 
28 indeterminate chondroid lesions has not resulted in a significant change in the 
findings of the publication.   
Lastly, the inter-observer reliability of the above described conventional MRI-findings 
remains untested as the analysis of the MRI-features was performed in consensus 
between the two readers and in case of disagreement the opinion of the most senior 
reviewer was accepted. However, this approach to the data analysis precludes 
assessment of inter-observer reliability of the above described MRI-features.  
In conclusion, the above described study identified several MRI features which allow 
accurate differentiation of low-grade chondroid tumours from high-grade 
chondrosarcomas of long bones. Therefore, this study significantly enhances the 
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understanding and knowledge that MRI plays in the accurate preoperative grading of 
chondrosarcomas of long bones. Furthermore, the findings of this study may result 
in a more accurate diagnosis prior to surgery and may significantly improve patient 
care.51
The sixth article (original article) included in the submitted PhD-thesis evaluates the 
role of staging in chondrosarcomas. Prior to this publication, it has been widely 
assumed that skeletal scintigraphy and Computed Tomography of the chest are 
mandatory in the initial staging of chondrosarcomas to assess for the presence of 
skeletal and pulmonary metastases. This management approach however has been 
based on evidence obtained from other sarcomas such as osteosarcoma and Ewing 
sarcoma which demonstrate skeletal and pulmonary metastases in 4-19% at initial 
presentation. The biological behaviour of chondrosarcomas is very different to 
osteosarcomas and Ewing sarcomas which tend to be more aggressive. Hence, this 
management approach was not evidence-based.  
We have therefore investigated the role of whole-body skeletal scintigraphy and 
Computed Tomography of the chest in the initial surgical staging of 
chondrosarcomas. In this retrospective study, we evaluated the bone scintigraphy 
reports and bone scintigraphs in 188 patients with chondrosarcomas. We discovered 
195 chondrosarcomas in 188 patients.   In our study, there were no patients with 
skeletal metastases at presentation. However, we discovered 3 patients with 
multifocal chondrosarcomas, 2 of whom had known Ollier’s disease and who would 
have been adequately imaged on the staging MRI-study. A third patient with 
multifocal chondrosarcoma was found to have a low-grade central chondrosarcoma 
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in the opposite femur. This finding did not alter surgical management as the lesion 
was observed and remained unchanged. We therefore concluded that there is little 
role of skeletal scintigraphy in the initial surgical staging of chondrosarcomas. The 
importance of this publication also lies in demonstrating that unlike in osteosarcoma 
and Ewing sarcoma, skeletal metastases in chondrosarcomas at presentation are 
very rare. This is of significance because previous studies have demonstrated that 
incidental enchondromas are commonly observed on routine MRI-examinations of 
the knee and shoulder.6,7 Since publication of our findings, the rarity of skeletal 
metastases in chondrosarcoma has been corroborated by Gulia et al. who evaluated 
69 patients with chondrosarcoma and identified only one patient with skeletal 
metastases (1.6% of all cases). Of note is, that in their study the single patient with 
skeletal metastases was also found to have concomitant pulmonary metastases. In 
contrast, Gulia et al. confirm that the prevalence of pulmonary metastases in 
chondrosarcoma of bone is significant being observed in 9.8% of all cases (6 patients) 
in their patient cohort.113
Similarly, a multicentre retrospective study published by Andreou et al. recently, 
evaluated the metastatic potential of grade 1 chondrosarcomas. The authors 
included 225 patients with grade 1 chondrosarcoma and found that 14 patients 
developed metastases after a median time of 49 months with a range of 4 to 125 
months. In their study, only two patients (0.9% of all patients) developed skeletal 
metastases whilst 12 patients (5.3% of all patients) developed pulmonary 
metastases. This recent study further supports our findings that skeletal metastases 
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are a rare occurrence in chondrosarcoma of bone in contrast to pulmonary 
metastases.114
We also assessed the CT-chest reports of all patients with chondrosarcoma at the 
time of diagnosis. In our study, we identified pulmonary metastases in approximately 
5% of chondrosarcomas at initial presentation. In contrast to skeletal scintigraphy, 
we found therefore evidence supporting the added value of Computed Tomography 
of the chest in the detection of pulmonary metastases in the initial staging of 
chondrosarcomas.  
There are limitations to our study.  
Firstly, of the 352 patients identified on the database with a chondrosarcoma, 154 
did not have bone scintigraphy images or reports available for review. Whilst review 
of clinical letters in these patients made no reference about the presence of skeletal 
metastases, we were therefore not in a position to definitely rule out that some of 
these patients may have presented with occult skeletal metastases.  
Secondly, of the 195 chondrosarcomas included in the study, only bone scintigrams, 
which demonstrated increased uptake outside the site of the chondrosarcoma 
according to the bone scintigraphy report were re-reported by the first author of the 
article. Whilst review of the clinical notes made no reference to the presence of 
skeletal metastases, we are again unable to rule out that some of these patients may 
have had occult skeletal metastases. Furthermore, the inter-observer reliability of 
the findings of the re-reported bone scintigrams has not been tested because bone 
scintigraphy studies were re-reported by the author of this thesis only.  
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Thirdly, in our patient cohort, three patients were diagnosed with synchronous 
multifocal chondrosarcomas. Whilst the presence of multifocal synchronous 
chondrosarcomas could be interpreted as skeletal metastases, two of these patients 
suffered from Ollier’s disease which is characterised by multifocal enchondromas in 
which malignant transformation is a well-recognised complication therefore strongly 
favouring that the presence of further chondrosarcomas is due to multiple 
chondrosarcomas rather than skeletal metastases. In contrast to the other two cases, 
the third patient with synchronous multifocal chondrosarcomas was not known to 
suffer from Ollier’s disease as there were no further manifestations on other imaging 
to suggest multiple enchondromas. The existence of multicentric primary 
chondrosarcomas in the absence of enchondromatosis or hereditary multiple 
exostosis remains uncertain.115  The third patient in our cohort was found to have a 
grade 2 chondrosarcoma of the left pubis, a grade 2 chondrosarcoma of the left 
proximal femur and a grade 1 chondrosarcoma of the right proximal femur. We 
therefore cannot exclude that one of the lesions in the left femur or pelvis 
represented a skip metastasis. The preoperative staging MRI-study accurately 
depicted both lesions. In contrast, the grade 1 chondrosarcoma of the contralateral 
right proximal femur was only depicted on the bone scintigraphy study. However, 
this lesion in view of its lower grade most likely represented a primary 
chondrosarcoma rather than a skeletal metastasis.  
Although some clinicians may wish to continue performing skeletal scintigraphy or 
may even consider whole-body MRI in the initial staging of chondrosarcomas, our 
findings highlight the rarity of skeletal metastases in this disease entity. Hence, the 
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presence of other adjacent chondroid lesions on skeletal scintigraphy or whole-body 
MRI should not be misinterpreted as skip metastases. This is of particular importance 
when one considers that incidental enchondromas are identified in approximately 
2% of all MRI-scans of the shoulder and in approximately 3% of all MRI-scans of the 
knee.6,7
In conclusion, this study, which forms part of the PhD-thesis demonstrates the rarity 
of skeletal metastases in chondrosarcoma of bone at presentation and highlights the 
significant prevalence of pulmonary metastases. This study therefore significantly 
advances the knowledge about the role of skeletal scintigraphy and Computed 
Tomography of the chest in the initial staging of chondrosarcoma of bone. 
In summary, the authors’ published work submitted for consideration of a PhD, 
investigates the theory that imaging may aid in the understanding of the 
pathogenesis of enchondromas and may aid in the diagnosis, grading and staging of 
chondrosarcomas of bone.  
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8.2 Future research 
Whilst the  author’s work has significantly advanced the understanding about the 
pathogenesis of enchondromas, the role of imaging in the diagnosis, grading and 
staging of chondrosarcomas, there remains diagnostic uncertainty in the 
differentiation of enchondromas from low-grade chondrosarcomas.  
Although the  author’s most recent publication demonstrated that the presence of 
more than 2/3 of endosteal scalloping on conventional MR shows a sensitivity of 
71.4% and a specificity of 92.9% in the differentiation of enchondromas from low-
grade chondrosarcomas and hence is the most sensitive feature on conventional 
MRI, the differentiation of the two disease entities remains challenging. Similarly, 
diffusion-weighted MRI cannot be used to differentiate between enchondromas and 
low-grade chondrosarcomas as demonstrated by the author. Furthermore, whilst 
dynamic-contrast enhanced MRI aids in the detection of high-grade 
chondrosarcomas, DCE-MRI crucially cannot be utilized to differentiate 
enchondromas from low-grade chondrosarcomas as published by the author of this 
thesis very recently (see Appendix 1).80
Other imaging techniques such as radiography, CT and PET/CT are of limited value in 
the distinction of the two disease entities. Other functional imaging modalities such 
as conventional MR-spectroscopy and hyperpolarized MRI have not been evaluated 
in the diagnosis of enchondromas and low-grade chondrosarcomas.  These functional 
imaging techniques have the potential to allow unique and fascinating insights into 
the tumour biology, into the molecular and genetic make-up of tumours in general 
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and of chondroid tumours in particular. It has been shown relatively recently that a 
majority of enchondromas and chondrosarcomas have somatic mutations in 
isocitrate dehydrogenase 1 and 2 (IDH 1 and 2) which produce the oncometabolite 
2-hydroxyglutarate.33 This oncometabolite could therefore potentially be identified 
and the concentration of this oncometabolite could be quantified non-invasively 
using conventional MR-spectroscopy or hyperpolarized MRI.  Quantification of this 
oncometabolite could therefore possibly result in a cut-off value which could 
differentiate enchondromas from low-grade chondrosarcomas more reliably.  These 
imaging techniques may therefore potentially hold the key to unravel the diagnostic 
uncertainty in the distinction of enchondromas from low-grade chondrosarcomas.  
Whilst molecular MRI-techniques warrant further research, at present, the 
differentiation of enchondromas from low-grade chondrosarcomas continues to be 
challenging. However, a very recent publication by the author of this thesis 
demonstrated that certain clinical and conventional MRI-features aid in the 
distinction of the two disease entities. In particular, the presence of more than 2/3 
of endosteal scalloping on conventional MRI and pain attributed to the lesion 
demonstrate a moderate sensitivity in the differentiation of enchondromas from 
low-grade chondrosarcomas whilst the presence of pain attributed to the lesion and 
more than 2/3 of endosteal scalloping are highly specific for a grade 1 
chondrosarcoma. The authors’ findings however require validation in a larger 
prospective patient cohort. Hence, further research is required to evaluate the role 
of conventional MRI in the differentiation of the two disease entities.   
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At present, there remains considerable diagnostic uncertainty in the differentiation 
of enchondromas from low-grade chondrosarcomas. In particular, the malignant 
potential of central chondroid lesions which do not demonstrate permeation on 
histopathology remains unknown. Hence, a major recommendation of this thesis is 
that future studies should focus on the malignant potential of low-grade central 
chondroid lesions which are not treated. Therefore, prospective long-term follow-up 
studies should be performed to assess the malignant potential of such low-grade 
chondroid lesions and to assess potential predictive imaging biomarkers. Surgery 
remains the only hope for cure in chondrosarcoma and the presence of skeletal 
metastases is associated with a bleak outcome. Advances in the molecular 
understanding of chondrosarcomas are likely to result in the development of non-
surgical therapies such as agents which specifically target mutations in 
chondrosarcoma cells. Therefore, the above described molecular imaging techniques 
may in future also allow the development of a personalized, molecular fingerprint of 
chondrosarcomas which in turn may allow non-invasive monitoring of treatment 
response in patients with chondrosarcoma beyond the current concept of 
conventional, anatomical imaging thus potentially resulting in a paradigm shift in 
imaging. Furthermore, molecular imaging may facilitate the development of new 
drugs which combine diagnostic and therapeutic capabilities (so-called theranostic 
drugs). In particular, the efficacy of drugs targeting IDH 1 and 2 mutations in 
chondrosarcomas could be combined with in-vivo and real-time assessment of 
treatment response in these patients using the above described functional imaging 
techniques. 
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Therefore, future imaging research in chondrosarcomas should focus on the role of 
conventional MRI in the differentiation of enchondromas from low-grade 
chondrosarcomas. However, imaging research should also investigate the potential 
role that the non-invasive detection and quantification of oncometabolites produced 
by genetic mutations may play in the diagnosis and treatment response assessment 
of chondrosarcomas.   
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